{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:42:07Z","timestamp":1792431727069,"version":"4.5.0"},"reference-count":378,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"DOI":"10.13039\/501100004462","name":"bilateral project of the National Research Council of Italy","doi-asserted-by":"publisher","award":["MD P01.008"],"award-info":[{"award-number":["MD P01.008"]}],"id":[{"id":"10.13039\/501100004462","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002261","name":"Russian Foundation for Basic Research","doi-asserted-by":"publisher","award":["15-54-78021"],"award-info":[{"award-number":["15-54-78021"]}],"id":[{"id":"10.13039\/501100002261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec><jats:title>:<\/jats:title><jats:p>The development of safe and efficacious enzyme-based human therapies has increased greatly in the last decades, thanks to remarkable advances in the understanding of the molecular mechanisms responsible for different diseases, and the characterization of the catalytic activity of relevant exogenous enzymes that may play a remedial effect in the treatment of such pathologies. Several enzyme-based biotherapeutics have been approved by FDA (the U.S. Food and Drug Administration) and EMA (the European Medicines Agency) and many are undergoing clinical trials. Apart from enzyme replacement therapy in human genetic diseases, which is not discussed in this review, approved enzymes for human therapy find applications in several fields, from cancer therapy to thrombolysis and the treatment, e.g., of clotting disorders, cystic fibrosis, lactose intolerance and collagen-based disorders. The majority of therapeutic enzymes are of microbial origin, the most convenient source due to fast, simple and cost-effective production and manipulation. The use of microbial recombinant enzymes has broadened prospects for human therapy but some hurdles such as high immunogenicity, protein instability, short half-life and low substrate affinity, still need to be tackled. Alternative sources of enzymes, with reduced side effects and improved activity, as well as genetic modification of the enzymes and novel delivery systems are constantly searched. Chemical modification strategies, targeted- and\/or nanocarrier-mediated delivery, directed evolution and site-specific mutagenesis, fusion proteins generated by genetic manipulation are the most explored tools to reduce toxicity and improve bioavailability and cellular targeting. This review provides a description of exogenous enzymes that are presently employed for the therapeutic management of human diseases with their current FDA\/EMA-approved status, along with those already experimented at the clinical level and potential promising candidates.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0929867328666210713094722","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T12:42:33Z","timestamp":1626266553000},"page":"411-452","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Use of Exogenous Enzymes in Human Therapy: Approved Drugs and Potential Applications"],"prefix":"10.2174","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2243-6716","authenticated-orcid":true,"given":"Patrizia","family":"Cioni","sequence":"first","affiliation":[{"name":"Institute of Biophysics, National Research Council, Via Moruzzi 1, 56124 Pisa,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0750-4095","authenticated-orcid":true,"given":"Edi","family":"Gabellieri","sequence":"additional","affiliation":[{"name":"Institute of Biophysics, National Research Council, Via Moruzzi 1, 56124 Pisa,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-0627","authenticated-orcid":true,"given":"Barbara","family":"Campanini","sequence":"additional","affiliation":[{"name":"Department of Food and Drug, University of Parma, Parco Area delle Scienze 23\/A, 43124 Parma,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6787-0594","authenticated-orcid":true,"given":"Stefano","family":"Bettati","sequence":"additional","affiliation":[{"name":"Institute of Biophysics, National Research Council, Via Moruzzi 1, 56124 Pisa,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3068-3714","authenticated-orcid":true,"given":"Samanta","family":"Raboni","sequence":"additional","affiliation":[{"name":"Institute of Biophysics, National Research Council, Via Moruzzi 1, 56124 Pisa,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/1873-3468.12121","volume":"590","author":"Selwan E.M.","year":"2016","unstructured":"Selwan E.M.; Finicle B.T.; Kim S.M.; Edinger A.L.; Attacking the supply wagons to starve cancer cells to death. FEBS Lett 2016,590(7),885-907","journal-title":"FEBS Lett"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"Pavlova N.N.","year":"2016","unstructured":"Pavlova N.N.; Thompson C.B.; The emerging hallmarks of cancer metabolism. Cell Metab 2016,23(1),27-47","journal-title":"Cell Metab"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/B978-0-12-416039-2.00015-X","volume":"502","author":"Cantor J.R.","year":"2012","unstructured":"Cantor J.R.; Panayiotou V.; Agnello G.; Georgiou G.; Stone E.M.; Engineering reduced-immunogenicity enzymes for amino acid depletion therapy in cancer. Methods Enzymol 2012,502,291-319","journal-title":"Methods Enzymol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2174\/0929867324666171006132729","volume":"26","author":"Pokrovsky V.S.","year":"2019","unstructured":"Pokrovsky V.S.; Chepikova O.E.; Davydov D.Z.; Zamyatnin A.A.; Lukashev A.N.; Lukasheva E.V.; Amino acid degrading enzymes and their application in cancer therapy. Curr Med Chem 2019,26(3),446-464","journal-title":"Curr Med Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1021\/acs.biochem.0c00116","volume":"59","author":"Lubkowski J.","year":"2020","unstructured":"Lubkowski J.; Vanegas J.; Chan W.K.; Lorenzi P.L.; Weinstein J.N.; Sukharev S.; Fushman D.; Rempe S.; Anishkin A.; Wlodawer A.; Mechanism of catalysis by l-asparaginase. Biochemistry 2020,59(20),1927-1945","journal-title":"Biochemistry"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.18388\/abp.2006_3291","volume":"53","author":"Michalska K.","year":"2006","unstructured":"Michalska K.; Jaskolski M.; Structural aspects of L-asparaginases, their friends and relations. Acta Biochim Pol 2006,53(4),627-640","journal-title":"Acta Biochim Pol"},{"key":"ref=7","first-page":"720","volume":"42","author":"Krishnapura P.R.","year":"2016","unstructured":"Krishnapura P.R.; Belur P.D.; Subramanya S.; A critical review on properties and applications of microbial l-asparaginases. Crit Rev Microbiol 2016,42(5),720-737","journal-title":"Crit Rev Microbiol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1084\/jem.98.6.565","volume":"98","author":"Kidd J.G.","year":"1953","unstructured":"Kidd J.G.; Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J Exp Med 1953,98(6),565-582","journal-title":"J Exp Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1084\/jem.127.6.1055","volume":"127","author":"Broome J.D.","year":"1968","unstructured":"Broome J.D.; Studies on the mechanism of tumor inhibition by L-asparaginase. Effects of the enzyme on asparagine levels in the blood, normal tissues, and 6C3HED lymphomas of mice: Differences in asparagine formation and utilization in asparaginase-sensitive and -resistant lymphoma cells. J Exp Med 1968,127(6),1055-1072","journal-title":"J Exp Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/978-3-642-99984-0_26","volume":"33","author":"Loeb E.","year":"1970","unstructured":"Loeb E.; Hill J.M.; Hill N.O.; MacLellan A.; Khan A.; Alexander T.R.; Adachi A.; Treatment of acute leukemia with L-asparaginase. Recent Results Cancer Res 1970,33,204-218","journal-title":"Recent Results Cancer Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1203:AID-CNCR15>3.0.CO;2-3","volume":"86","author":"Aguayo A.","year":"1999","unstructured":"Aguayo A.; Cortes J.; Thomas D.; Pierce S.; Keating M.; Kantarjian H.; Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer 1999,86(7),1203-1209","journal-title":"Cancer"},{"key":"ref=12","first-page":"416","volume":"65","author":"Aljewari H.","year":"2010","unstructured":"Aljewari H.; Nader M.; Al-Faisal A.; Weerapreeyakul N.; Sahapat S.; High efficiency, selectivity against cancer cell line of purified L-Asparaginase from pathogenic Escherichia coli. World Acad Sci Eng Technol 2010,65,416-421","journal-title":"World Acad Sci Eng Technol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/j.1365-2141.2005.05694.x","volume":"130","author":"Ando M.","year":"2005","unstructured":"Ando M.; Sugimoto K.; Kitoh T.; Sasaki M.; Mukai K.; Ando J.; Egashira M.; Schuster S.M.; Oshimi K.; Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol 2005,130(6),860-868","journal-title":"Br J Haematol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hoc.2009.11.014","volume":"24","author":"Pieters R.","year":"2010","unstructured":"Pieters R.; Carroll W.L.; Biology and treatment of acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2010,24(1),1-18","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/ijc.2910190118","volume":"19","author":"Yunis A.A.","year":"1977","unstructured":"Yunis A.A.; Arimura G.K.; Russin D.J.; Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: Sensitivity to asparaginase. Int J Cancer 1977,19(1),128-135","journal-title":"Int J Cancer"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00003088-200544040-00003","volume":"44","author":"Avramis V.I.","year":"2005","unstructured":"Avramis V.I.; Panosyan E.H.; Pharmacokinetic\/pharmacodynamic relationships of asparaginase formulations: The past, the present and recommendations for the future. Clin Pharmacokinet 2005,44(4),367-393","journal-title":"Clin Pharmacokinet"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/ped.13457","volume":"60","author":"Kato M.","year":"2018","unstructured":"Kato M.; Manabe A.; Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int (Roma) 2018,60(1),4-12","journal-title":"Pediatr Int (Roma)"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.pcl.2014.09.004","volume":"62","author":"Bhojwani D.","year":"2015","unstructured":"Bhojwani D.; Yang J.J.; Pui C.H.; Biology of childhood acute lymphoblastic leukemia. Pediatr Clin North Am 2015,62(1),47-60","journal-title":"Pediatr Clin North Am"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1040-8428(98)00015-8","volume":"28","author":"M&#xFC;ller H.J.","year":"1998","unstructured":"M&#xFC;ller H.J.; Boos J.; Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998,28(2),97-113","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1200\/JCO.2002.07.300","volume":"20","author":"Perel Y.","year":"2002","unstructured":"Perel Y.; Auvrignon A.; Leblanc T.; Vannier J.P.; Michel G.; Nelken B.; Gandemer V.; Schmitt C.; Lamagnere J.P.; De Lumley L.; Bader-Meunier B.; Couillaud G.; Schaison G.; Landman-Parker J.; Thuret I.; Dalle J.H.; Baruchel A.; Leverger G.; Immunology G.L.F.S.P.H.; Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: Results of a prospective randomized trial, LAME 89\/91. Leuc&#xE1;mie Aiq&#xFC;e My&#xE9;lo&#xEF;de Enfant. J Clin Oncol 2002,20(12),2774-2782","journal-title":"J Clin Oncol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1182\/blood-2013-03-493163","volume":"122","author":"Willems L.","year":"2013","unstructured":"Willems L.; Jacque N.; Jacquel A.; Neveux N.; Maciel T.T.; Lambert M.; Schmitt A.; Poulain L.; Green A.S.; Uzunov M.; Kosmider O.; Radford-Weiss I.; Moura I.C.; Auberger P.; Ifrah N.; Bardet V.; Chapuis N.; Lacombe C.; Mayeux P.; Tamburini J.; Bouscary D.; Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood 2013,122(20),3521-3532","journal-title":"Blood"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","volume":"29","author":"Yamaguchi M.","year":"2011","unstructured":"Yamaguchi M.; Kwong Y.L.; Kim W.S.; Maeda Y.; Hashimoto C.; Suh C.; Izutsu K.; Ishida F.; Isobe Y.; Sueoka E.; Suzumiya J.; Kodama T.; Kimura H.; Hyo R.; Nakamura S.; Oshimi K.; Suzuki R.; Phase I.I.; Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: The NK-Cell Tumor Study Group study. J Clin Oncol 2011,29(33),4410-4416","journal-title":"J Clin Oncol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1097\/MPA.0b013e318247d903","volume":"41","author":"Dufour E.","year":"2012","unstructured":"Dufour E.; Gay F.; Aguera K.; Scoazec J.Y.; Horand F.; Lorenzi P.L.; Godfrin Y.; Pancreatic tumor sensitivity to plasma L-asparagine starvation. Pancreas 2012,41(6),940-948","journal-title":"Pancreas"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1158\/1535-7163.MCT-08-0589","volume":"7","author":"Lorenzi P.L.","year":"2008","unstructured":"Lorenzi P.L.; Llamas J.; Gunsior M.; Ozbun L.; Reinhold W.C.; Varma S.; Ji H.; Kim H.; Hutchinson A.A.; Kohn E.C.; Goldsmith P.K.; Birrer M.J.; Weinstein J.N.; Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther 2008,7(10),3123-3128","journal-title":"Mol Cancer Ther"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1158\/1535-7163.MCT-06-0447","volume":"5","author":"Lorenzi P.L.","year":"2006","unstructured":"Lorenzi P.L.; Reinhold W.C.; Rudelius M.; Gunsior M.; Shankavaram U.; Bussey K.J.; Scherf U.; Eichler G.S.; Martin S.E.; Chin K.; Gray J.W.; Kohn E.C.; Horak I.D.; Von Hoff D.D.; Raffeld M.; Goldsmith P.K.; Caplen N.J.; Weinstein J.N.; Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther 2006,5(11),2613-2623","journal-title":"Mol Cancer Ther"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.addr.2007.04.018","volume":"60","author":"Pasut G.","year":"2008","unstructured":"Pasut G.; Sergi M.; Veronese F.M.; Anti-cancer PEG-enzymes: 30 years old, but still a current approach. Adv Drug Deliv Rev 2008,60(1),69-78","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0378-5173(02)00046-7","volume":"237","author":"Soares A.L.","year":"2002","unstructured":"Soares A.L.; Guimar&#xE3;es G.M.; Polakiewicz B.; de Moraes Pitombo R.N.; Abrah&#xE3;o-Neto J.; Effects of polyethylene glycol attachment on physicochemical and biological stability of E. coli L-asparaginase. Int J Pharm 2002,237(1-2),163-170","journal-title":"Int J Pharm"},{"key":"ref=28","first-page":"164","volume":"53","author":"Melik-Nubarov N.S.","year":"2017","unstructured":"Melik-Nubarov N.S.; Grozdova I.D.; Lomakina G.Y.; Pokrovskaya M.V.; Pokrovski V.S.; Aleksandrova S.S.; Abakumova O.Y.; Podobed O.V.; Grishin D.V.; Sokolov N.N.; PEGylated recombinant L-asparaginase from Erwinia carotovora: Production, properties, and potential applications. Prikl Biokhim Mikrobiol 2017,53(2),164-172","journal-title":"Prikl Biokhim Mikrobiol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2217\/ijh-2016-0002","volume":"5","author":"Thomas X.","year":"2016","unstructured":"Thomas X.; Le Jeune C.; Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia. Int J Hematol Oncol 2016,5(1),11-25","journal-title":"Int J Hematol Oncol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.msec.2019.01.003","volume":"98","author":"Brito A.E.M.","year":"2019","unstructured":"Brito A.E.M.; Pessoa A.; Converti A.; Rangel-Yagui C.O.; Silva J.A.D.; Apolin&#xE1;rio A.C.; Poly (lactic-co-glycolic acid) nanospheres allow for high l-asparaginase encapsulation yield and activity. Mater Sci Eng C 2019,98,524-534","journal-title":"Mater Sci Eng C"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.colsurfb.2016.03.046","volume":"143","author":"Wan S.","year":"2016","unstructured":"Wan S.; He D.; Yuan Y.; Yan Z.; Zhang X.; Zhang J.; Chitosan-modified lipid nanovesicles for efficient systemic delivery of l-asparaginase. Colloids Surf B Biointerfaces 2016,143,278-284","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"11026","DOI":"10.1021\/bi901397h","volume":"48","author":"Cantor J.R.","year":"2009","unstructured":"Cantor J.R.; Stone E.M.; Chantranupong L.; Georgiou G.; The human asparaginase-like protein 1 hASRGL1 is an Ntn hydrolase with beta-aspartyl peptidase activity. Biochemistry 2009,48(46),11026-11031","journal-title":"Biochemistry"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1042\/bj20031496","volume":"378","author":"Saarela J.","year":"2004","unstructured":"Saarela J.; Oinonen C.; Jalanko A.; Rouvinen J.; Peltonen L.; Autoproteolytic activation of human aspartylglucosaminidase. Biochem J 2004,378(Pt 2),363-371","journal-title":"Biochem J"},{"key":"ref=34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178174","volume":"12","author":"Belviso S.","year":"2017","unstructured":"Belviso S.; Iuliano R.; Amato R.; Perrotti N.; Menniti M.; The human asparaginase enzyme (ASPG) inhibits growth in leukemic cells. PLoS One 2017,12(5)","journal-title":"PLoS One"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s11274-019-2731-9","volume":"35","author":"Beckett A.","year":"2019","unstructured":"Beckett A.; Gervais D.; What makes a good new therapeutic L-asparaginase? World J Microbiol Biotechnol 2019,35(10),152","journal-title":"World J Microbiol Biotechnol"},{"key":"ref=36","first-page":"15394","volume":"9","author":"Al-Dulimi A.G.","year":"2020","unstructured":"Al-Dulimi A.G.; Al-Saffar A.Z.; Sulaiman G.M.; Khalil K.A.A.; Khashan K.S.; Al-Shmgani H.S.A.; Ahmed E.M.; Immobilization of L-asparaginase on gold nanoparticles for novel drug delivery approach as anti-cancer agent against human breast carcinoma cells. J Mater Res 2020,9(6),15394-15411","journal-title":"J Mater Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3390\/ijms17030363","volume":"17","author":"Xiong L.","year":"2016","unstructured":"Xiong L.; Teng J.L.L.; Botelho M.G.; Lo R.C.; Lau S.K.P.; Woo P.C.Y.; Arginine metabolism in bacterial pathogenesis and cancer therapy. Int J Mol Sci 2016,17(3),363","journal-title":"Int J Mol Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/cncr.20057","volume":"100","author":"Dillon B.J.","year":"2004","unstructured":"Dillon B.J.; Prieto V.G.; Curley S.A.; Ensor C.M.; Holtsberg F.W.; Bomalaski J.S.; Clark M.A.; Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: A method for identifying cancers sensitive to arginine deprivation. Cancer 2004,100(4),826-833","journal-title":"Cancer"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2015.04.020","volume":"364","author":"Qiu F.","year":"2015","unstructured":"Qiu F.; Huang J.; Sui M.; Targeting arginine metabolism pathway to treat arginine-dependent cancers. Cancer Lett 2015,364(1),1-7","journal-title":"Cancer Lett"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/13543776.2017.1254194","volume":"27","author":"Fernandes H.S.","year":"2017","unstructured":"Fernandes H.S.; Silva Teixeira C.S.; Fernandes P.A.; Ramos M.J.; Cerqueira N.M.; Amino acid deprivation using enzymes as a targeted therapy for cancer and viral infections. Expert Opin Ther Pat 2017,27(3),283-297","journal-title":"Expert Opin Ther Pat"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1042\/CBI20100451","volume":"34","author":"Bobak Y.P.","year":"2010","unstructured":"Bobak Y.P.; Vynnytska B.O.; Kurlishchuk Y.V.; Sibirny A.A.; Stasyk O.V.; Cancer cell sensitivity to arginine deprivation in vitro is not determined by endogenous levels of arginine metabolic enzymes. Cell Biol Int 2010,34(11),1085-1089","journal-title":"Cell Biol Int"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"4747","DOI":"10.1007\/s00253-016-7490-z","volume":"100","author":"Han R.Z.","year":"2016","unstructured":"Han R.Z.; Xu G.C.; Dong J.J.; Ni Y.; Arginine deiminase: Recent advances in discovery, crystal structure, and protein engineering for improved properties as an anti-tumor drug. Appl Microbiol Biotechnol 2016,100(11),4747-4760","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=43","first-page":"4522","volume":"50","author":"Miyazaki K.","year":"1990","unstructured":"Miyazaki K.; Takaku H.; Umeda M.; Fujita T.; Huang W.D.; Kimura T.; Yamashita J.; Horio T.; Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line. Cancer Res 1990,50(15),4522-4527","journal-title":"Cancer Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1038\/onc.2016.37","volume":"35","author":"Patil M.D.","year":"2016","unstructured":"Patil M.D.; Bhaumik J.; Babykutty S.; Banerjee U.C.; Fukumura D.; Arginine dependence of tumor cells: Targeting a chink in cancer\u2019s armor. Oncogene 2016,35(38),4957-4972","journal-title":"Oncogene"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0168-3659(02)00042-1","volume":"80","author":"Holtsberg F.W.","year":"2002","unstructured":"Holtsberg F.W.; Ensor C.M.; Steiner M.R.; Bomalaski J.S.; Clark M.A.; Poly(ethylene glycol) (PEG) conjugated arginine deiminase: Effects of PEG formulations on its pharmacological properties. J Control Release 2002,80(1-3),259-271","journal-title":"J Control Release"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"589","DOI":"10.5306\/wjco.v11.i8.589","volume":"11","author":"Chow A.K.","year":"2020","unstructured":"Chow A.K.; Yau S.W.; Ng L.; Novel molecular targets in hepatocellular carcinoma. World J Clin Oncol 2020,11(8),589-605","journal-title":"World J Clin Oncol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13045-017-0509-9","volume":"10","author":"Fung M.K.L.","year":"2017","unstructured":"Fung M.K.L.; Chan G.C.F.; Drug-induced amino acid deprivation as strategy for cancer therapy. J Hematol Oncol 2017,10(1),144","journal-title":"J Hematol Oncol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/13543776.2018.1508452","volume":"28","author":"Dhankhar R.","year":"2018","unstructured":"Dhankhar R.; Gulati P.; Kumar S.; Kapoor R.K.; Arginine-lowering enzymes against cancer: A technocommercial analysis through patent landscape. Expert Opin Ther Pat 2018,28(8),603-614","journal-title":"Expert Opin Ther Pat"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/sj.bjc.6600681","volume":"88","author":"Philip R.","year":"2003","unstructured":"Philip R.; Campbell E.; Wheatley D.N.; Arginine deprivation, growth inhibition and tumour cell death: 2. Enzymatic degradation of arginine in normal and malignant cell cultures. Br J Cancer 2003,88(4),613-623","journal-title":"Br J Cancer"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/BF03033696","volume":"8","author":"Wheatley D.N.","year":"2002","unstructured":"Wheatley D.N.; Campbell E.; Arginine catabolism, liver extracts and cancer. Pathol Oncol Res 2002,8(1),18-25","journal-title":"Pathol Oncol Res"},{"key":"ref=51","author":"Li L.H.","year":"2013","unstructured":"Li L.H.; Wang Y.; Chen J.; Cheng B.; Hu J.H.; Zhou Y.H.; Gao X.; Gao L.C.; Mei X.F.; Sun M.Y.; Zhang Z.M.; Song H.F.; An Engineered Arginase FC Protein Inhibits Tumor Growth in vitro and in vivo. Evidence-Based Complementary and Alternative Medicine 2013","journal-title":"Evidence-Based Complementary and Alternative Medicine"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1021\/cb900267j","volume":"5","author":"Stone E.M.","year":"2010","unstructured":"Stone E.M.; Glazer E.S.; Chantranupong L.; Cherukuri P.; Breece R.M.; Tierney D.L.; Curley S.A.; Iverson B.L.; Georgiou G.; Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines. ACS Chem Biol 2010,5(3),333-342","journal-title":"ACS Chem Biol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s10637-014-0200-8","volume":"33","author":"Yau T.","year":"2015","unstructured":"Yau T.; Cheng P.N.; Chan P.; Chen L.; Yuen J.; Pang R.; Fan S.T.; Wheatley D.N.; Poon R.T.; Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma. Invest New Drugs 2015,33(2),496-504","journal-title":"Invest New Drugs"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/ijc.30051","volume":"139","author":"Fultang L.","year":"2016","unstructured":"Fultang L.; Vardon A.; De Santo C.; Mussai F.; Molecular basis and current strategies of therapeutic arginine depletion for cancer. Int J Cancer 2016,139(3),501-509","journal-title":"Int J Cancer"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1007\/s00253-020-10484-4","volume":"104","author":"Chung S.F.","year":"2020","unstructured":"Chung S.F.; Kim C.F.; Tam S.Y.; Choi M.C.; So P.K.; Wong K.Y.; Leung Y.C.; Lo W.H.; A bioengineered arginine-depleting enzyme as a long-lasting therapeutic agent against cancer. Appl Microbiol Biotechnol 2020,104(9),3921-3934","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"R453","DOI":"10.1016\/j.cub.2014.03.034","volume":"24","author":"Schieber M.","year":"2014","unstructured":"Schieber M.; Chandel N.S.; ROS function in redox signaling and oxidative stress. Curr Biol 2014,24(10),R453-R462","journal-title":"Curr Biol"},{"key":"ref=57","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-8796-2","author":"Hoffman R.M.","year":"2019","unstructured":"Hoffman R.M.; Methionine Dependence of Cancer and Aging: Methods and protocols 2019","journal-title":"Methionine Dependence of Cancer and Aging: Methods and protocols"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.bcp.2018.05.003","volume":"154","author":"Chaturvedi S.","year":"2018","unstructured":"Chaturvedi S.; Hoffman R.M.; Bertino J.R.; Exploiting methionine restriction for cancer treatment. Biochem Pharmacol 2018,154,170-173","journal-title":"Biochem Pharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.ctrv.2012.01.004","volume":"38","author":"Cavuoto P.","year":"2012","unstructured":"Cavuoto P.; Fenech M.F.; A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension. Cancer Treat Rev 2012,38(6),726-736","journal-title":"Cancer Treat Rev"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00253-009-2303-2","volume":"86","author":"El-Sayed A.S.","year":"2010","unstructured":"El-Sayed A.S.; Microbial L-methioninase: Production, molecular characterization, and therapeutic applications. Appl Microbiol Biotechnol 2010,86(2),445-467","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"92","DOI":"10.32607\/20758251-2013-5-3-92-98","volume":"5","author":"Morozova E.A.","year":"2013","unstructured":"Morozova E.A.; Kulikova V.V.; Yashin D.V.; Anufrieva N.V.; Anisimova N.Y.; Revtovich S.V.; Kotlov M.I.; Belyi Y.F.; Pokrovsky V.S.; Demidkina T.V.; Kinetic parameters and cytotoxic activity of recombinant methionine &#x3B3;-lyase from Clostridium tetani, Clostridium sporogenes, Porphyromonas gingivalis and Citrobacter freundii. Acta Naturae 2013,5(3),92-98","journal-title":"Acta Naturae"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1517\/14712598.2015.963050","volume":"15","author":"Hoffman R.M.","year":"2015","unstructured":"Hoffman R.M.; Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: A 40-year odyssey. Expert Opin Biol Ther 2015,15(1),21-31","journal-title":"Expert Opin Biol Ther"},{"key":"ref=63","first-page":"643","volume":"6","author":"Poirson-Bichat F.","year":"2000","unstructured":"Poirson-Bichat F.; Gon&#xE7;alves R.A.; Miccoli L.; Dutrillaux B.; Poupon M.F.; Methionine depletion enhances the antitumoral efficacy of cytotoxic agents in drug-resistant human tumor xenografts. Clin Cancer Res 2000,6(2),643-653","journal-title":"Clin Cancer Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/s41591-019-0423-5","volume":"25","author":"Wang Z.","year":"2019","unstructured":"Wang Z.; Yip L.Y.; Lee J.H.J.; Wu Z.; Chew H.Y.; Chong P.K.W.; Teo C.C.; Ang H.Y.; Peh K.L.E.; Yuan J.; Ma S.; Choo L.S.K.; Basri N.; Jiang X.; Yu Q.; Hillmer A.M.; Lim W.T.; Lim T.K.H.; Takano A.; Tan E.H.; Tan D.S.W.; Ho Y.S.; Lim B.; Tam W.L.; Methionine is a metabolic dependency of tumor-initiating cells. Nat Med 2019,25(5),825-837","journal-title":"Nat Med"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/ijc.24104","volume":"124","author":"Hu J.","year":"2009","unstructured":"Hu J.; Cheung N.K.V.; Methionine depletion with recombinant methioninase: in vitro and in vivo efficacy against neuroblastoma and its synergism with chemotherapeutic drugs. Int J Cancer 2009,124(7),1700-1706","journal-title":"Int J Cancer"},{"key":"ref=66","first-page":"4017","volume":"61","author":"Kokkinakis D.M.","year":"2001","unstructured":"Kokkinakis D.M.; Hoffman R.M.; Frenkel E.P.; Wick J.B.; Han Q.; Xu M.; Tan Y.; Schold S.C.; Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice. Cancer Res 2001,61(10),4017-4023","journal-title":"Cancer Res"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"13000","DOI":"10.1073\/pnas.1917362117","volume":"117","author":"Lu W.C.","year":"2020","unstructured":"Lu W.C.; Saha A.; Yan W.; Garrison K.; Lamb C.; Pandey R.; Irani S.; Lodi A.; Lu X.; Tiziani S.; Zhang Y.J.; Georgiou G.; DiGiovanni J.; Stone E.; Enzyme-mediated depletion of serum l-Met abrogates prostate cancer growth via multiple mechanisms without evidence of systemic toxicity. Proc Natl Acad Sci USA 2020,117(23),13000-13011","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=68","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/506287","volume":"2014","author":"Sharma B.","year":"2014","unstructured":"Sharma B.; Singh S.; Kanwar S.S.; L-Methionase: A therapeutic enzyme to treat malignancies. BioMed Res Int 2014,2014","journal-title":"BioMed Res Int"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.bbapap.2018.09.011","volume":"1866","author":"Raboni S.","year":"2018","unstructured":"Raboni S.; Revtovich S.; Demitri N.; Giabbai B.; Storici P.; Cocconcelli C.; Faggiano S.; Rosini E.; Pollegioni L.; Galati S.; Buschini A.; Morozova E.; Kulikova V.; Nikulin A.; Gabellieri E.; Cioni P.; Demidkina T.; Mozzarelli A.; Engineering methionine &#x3B3;-lyase from Citrobacter freundii for anticancer activity. Biochim Biophys Acta Proteins Proteomics 2018,1866(12),1260-1270","journal-title":"Biochim Biophys Acta Proteins Proteomics"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12929-014-0065-3","volume":"21","author":"Guillen K.P.","year":"2014","unstructured":"Guillen K.P.; Kurkjian C.; Harrison R.G.; Targeted enzyme prodrug therapy for metastatic prostate cancer-a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase. J Biomed Sci 2014,21,65","journal-title":"J Biomed Sci"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3109\/07357907.2013.840383","volume":"31","author":"Van Rite B.D.","year":"2013","unstructured":"Van Rite B.D.; Krais J.J.; Cherry M.; Sikavitsas V.I.; Kurkjian C.; Harrison R.G.; Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature. Cancer Invest 2013,31(8),505-510","journal-title":"Cancer Invest"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"6673","DOI":"10.1158\/0008-5472.CAN-04-1822","volume":"64","author":"Yang Z.","year":"2004","unstructured":"Yang Z.; Wang J.; Lu Q.; Xu J.; Kobayashi Y.; Takakura T.; Takimoto A.; Yoshioka T.; Lian C.; Chen C.; Zhang D.; Zhang Y.; Li S.; Sun X.; Tan Y.; Yagi S.; Frenkel E.P.; Hoffman R.M.; PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res 2004,64(18),6673-6678","journal-title":"Cancer Res"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/0-306-47932-X_5","volume":"519","author":"Hoffman R.M.","year":"2003","unstructured":"Hoffman R.M.; PEG-methioninase. Adv Exp Med Biol 2003,519,69-79","journal-title":"Adv Exp Med Biol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1166\/jbn.2015.2062","volume":"11","author":"Xin L.","year":"2015","unstructured":"Xin L.; Caot J.Q.; Liu C.; Zeng F.; Cheng H.; Hu X.Y.; Shao J.H.; Evaluation of rMETase-Loaded Stealth PLGA\/Liposomes Modified with Anti-CAGE scFV for Treatment of Gastric Carcinoma. J Biomed Nanotechnol 2015,11(7),1153-1161","journal-title":"J Biomed Nanotechnol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1166\/jnn.2018.14333","volume":"18","author":"Morozova E.A.","year":"2018","unstructured":"Morozova E.A.; Kulikova V.V.; Faggiano S.; Raboni S.; Gabellieri E.; Cioni P.; Anufrieva N.V.; Revtovich S.V.; Demidkina T.; Mozzarelli A.; Soluble and Nanoporous Silica Gel-Entrapped C. freundii Methionine &#x3B3;-Lyase. J Nanosci Nanotechnol 2018,18(3),2210-2219","journal-title":"J Nanosci Nanotechnol"},{"key":"ref=76","first-page":"2696","volume":"60","author":"Miki K.","year":"2000","unstructured":"Miki K.; Al-Refaie W.; Xu M.; Jiang P.; Tan Y.; Bouvet M.; Zhao M.; Gupta A.; Chishima T.; Shimada H.; Makuuchi M.; Moossa A.R.; Hoffman R.M.; Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment. Cancer Res 2000,60(10),2696-2702","journal-title":"Cancer Res"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1021\/cb300335j","volume":"7","author":"Stone E.","year":"2012","unstructured":"Stone E.; Paley O.; Hu J.; Ekerdt B.; Cheung N.K.; Georgiou G.; De novo engineering of a human cystathionine-&#x3B3;-lyase for systemic (L)-Methionine depletion cancer therapy. ACS Chem Biol 2012,7(11),1822-1829","journal-title":"ACS Chem Biol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/cam4.1086","volume":"6","author":"Gay F.","year":"2017","unstructured":"Gay F.; Aguera K.; S&#xE9;n&#xE9;chal K.; Tainturier A.; Berlier W.; Maucort-Boulch D.; Honnorat J.; Horand F.; Godfrin Y.; Bourgeaux V.; Methionine tumor starvation by erythrocyte-encapsulated methionine gamma-lyase activity controlled with per os vitamin B6. Cancer Med 2017,6(6),1437-1452","journal-title":"Cancer Med"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cbpa.2018.11.002","volume":"48","author":"Bak D.W.","year":"2019","unstructured":"Bak D.W.; Bechtel T.J.; Falco J.A.; Weerapana E.; Cysteine reactivity across the subcellular universe. Curr Opin Chem Biol 2019,48,96-105","journal-title":"Curr Opin Chem Biol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"Dixon S.J.","year":"2012","unstructured":"Dixon S.J.; Lemberg K.M.; Lamprecht M.R.; Skouta R.; Zaitsev E.M.; Gleason C.E.; Patel D.N.; Bauer A.J.; Cantley A.M.; Yang W.S.; Morrison B.; Stockwell B.R.; Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 2012,149(5),1060-1072","journal-title":"Cell"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/nm.4232","volume":"23","author":"Cramer S.L.","year":"2017","unstructured":"Cramer S.L.; Saha A.; Liu J.; Tadi S.; Tiziani S.; Yan W.; Triplett K.; Lamb C.; Alters S.E.; Rowlinson S.; Zhang Y.J.; Keating M.J.; Huang P.; DiGiovanni J.; Georgiou G.; Stone E.; Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth. Nat Med 2017,23(1),120-127","journal-title":"Nat Med"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","volume":"569","author":"Wang W.","year":"2019","unstructured":"Wang W.; Green M.; Choi J.E.; Gij&#xF3;n M.; Kennedy P.D.; Johnson J.K.; Liao P.; Lang X.; Kryczek I.; Sell A.; Xia H.; Zhou J.; Li G.; Li J.; Li W.; Wei S.; Vatan L.; Zhang H.; Szeliga W.; Gu W.; Liu R.; Lawrence T.S.; Lamb C.; Tanno Y.; Cieslik M.; Stone E.; Georgiou G.; Chan T.A.; Chinnaiyan A.; Zou W.; CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 2019,569(7755),270-274","journal-title":"Nature"},{"key":"ref=83","author":"Bonifacio V.D.B.","year":"2020","unstructured":"Bonifacio V.D.B.; Pereira S.A.; Serpa J.; Vicente J.B.; Cysteine metabolic circuitries: druggable targets in cancer. Br J Cancer 2020","journal-title":"Br J Cancer"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41698-019-0088-z","volume":"3","author":"Kshattry S.","year":"2019","unstructured":"Kshattry S.; Saha A.; Gries P.; Tiziani S.; Stone E.; Georgiou G.; DiGiovanni J.; Enzyme-mediated depletion of l-cyst(e)ine synergizes with thioredoxin reductase inhibition for suppression of pancreatic tumor growth. NPJ Precis Oncol 2019,3,16","journal-title":"NPJ Precis Oncol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1182\/blood.2019898114","volume":"134","author":"Jones C.L.","year":"2019","unstructured":"Jones C.L.; Stevens B.M.; D\u2019Alessandro A.; Culp-Hill R.; Reisz J.A.; Pei S.; Gustafson A.; Khan N.; DeGregori J.; Pollyea D.A.; Jordan C.T.; Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. Blood 2019,134(4),389-394","journal-title":"Blood"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/msb.2012.20","volume":"8","author":"Graham N.A.","year":"2012","unstructured":"Graham N.A.; Tahmasian M.; Kohli B.; Komisopoulou E.; Zhu M.; Vivanco I.; Teitell M.A.; Wu H.; Ribas A.; Lo R.S.; Mellinghoff I.K.; Mischel P.S.; Graeber T.G.; Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Mol Syst Biol 2012,8,589","journal-title":"Mol Syst Biol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"16439","DOI":"10.1039\/C9RA02054C","volume":"9","author":"Liu Y.","year":"2019","unstructured":"Liu Y.; Nan X.; Shi W.; Liu X.; He Z.; Sun Y.N.; Ge D.T.; A glucose biosensor based on the immobilization of glucose oxidase and Au nanocomposites with polynorepinephrine. RSC Advances 2019,9(29),16439-16446","journal-title":"RSC Advances"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"8026","DOI":"10.7150\/thno.38261","volume":"9","author":"Yu S.","year":"2019","unstructured":"Yu S.; Chen Z.; Zeng X.; Chen X.; Gu Z.; Advances in nanomedicine for cancer starvation therapy. Theranostics 2019,9(26),8026-8047","journal-title":"Theranostics"},{"key":"ref=89","volume":"3","author":"Wang C.H.","year":"2020","unstructured":"Wang C.H.; Yang J.X.; Dong C.Y.; Shi S.; Glucose Oxidase-Related Cancer Therapies. Adv Ther 2020,3(10)","journal-title":"Adv Ther"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.biotechadv.2009.04.003","volume":"27","author":"Bankar S.B.","year":"2009","unstructured":"Bankar S.B.; Bule M.V.; Singhal R.S.; Ananthanarayan L.; Glucose oxidase--an overview. Biotechnol Adv 2009,27(4),489-501","journal-title":"Biotechnol Adv"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"9929","DOI":"10.1039\/C8CC03599G","volume":"54","author":"Dinda S.","year":"2018","unstructured":"Dinda S.; Sarkar S.; Das P.K.; Glucose oxidase mediated targeted cancer-starving therapy by biotinylated self-assembled vesicles. Chem Commun (Camb) 2018,54(71),9929-9932","journal-title":"Chem Commun (Camb)"},{"key":"ref=92","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201903895","volume":"15","author":"Wang M.","year":"2019","unstructured":"Wang M.; Wang D.; Chen Q.; Li C.; Li Z.; Lin J.; Recent advances in glucose-oxidase-based nanocomposites for tumor therapy. Small 2019,15(51)","journal-title":"Small"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"15030","DOI":"10.1021\/acsami.8b01818","volume":"10","author":"Zhang Y.H.","year":"2018","unstructured":"Zhang Y.H.; Qiu W.X.; Zhang M.; Zhang L.; Zhang X.Z.; MnO2 motor: A prospective cancer-starving therapy promoter. ACS Appl Mater Interfaces 2018,10(17),15030-15039","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=94","author":"Sun D.","unstructured":"Sun D.; Qi G.; Ma K.; Qu X.; Xu W.; Xu S.; Jin Y.; Tumor microenvironment-activated degradable multifunctional nanoreactor for synergistic cancer therapy and glucose SERS feedback. iScience, 2020, 23(7), 101274."},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc1891","volume":"6","author":"Pastan I.","year":"2006","unstructured":"Pastan I.; Hassan R.; Fitzgerald D.J.; Kreitman R.J.; Immunotoxin therapy of cancer. Nat Rev Cancer 2006,6(7),559-565","journal-title":"Nat Rev Cancer"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1146\/annurev.med.58.070605.115320","volume":"58","author":"Pastan I.","year":"2007","unstructured":"Pastan I.; Hassan R.; FitzGerald D.J.; Kreitman R.J.; Immunotoxin treatment of cancer. Annu Rev Med 2007,58,221-237","journal-title":"Annu Rev Med"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/08830185.2017.1284211","volume":"36","author":"Akbari B.","year":"2017","unstructured":"Akbari B.; Farajnia S.; Ahdi Khosroshahi S.; Safari F.; Yousefi M.; Dariushnejad H.; Rahbarnia L.; Immunotoxins in cancer therapy: Review and update. Int Rev Immunol 2017,36(4),207-219","journal-title":"Int Rev Immunol"},{"key":"ref=98","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317692226","volume":"39","author":"Allahyari H.","year":"2017","unstructured":"Allahyari H.; Heidari S.; Ghamgosha M.; Saffarian P.; Amani J.; Immunotoxin: A new tool for cancer therapy. Tumour Biol 2017,39(2)","journal-title":"Tumour Biol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1007\/s00253-020-10457-7","volume":"104","author":"Wong J.H.","year":"2020","unstructured":"Wong J.H.; Bao H.; Ng T.B.; Chan H.H.L.; Ng C.C.W.; Man G.C.W.; Wang H.; Guan S.; Zhao S.; Fang E.F.; Rolka K.; Liu Q.; Li C.; Sha O.; Xia L.; New ribosome-inactivating proteins and other proteins with protein synthesis-inhibiting activities. Appl Microbiol Biotechnol 2020,104(10),4211-4226","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/toxins9110344","volume":"9","author":"Rust A.","year":"2017","unstructured":"Rust A.; Partridge L.J.; Davletov B.; Hautbergue G.M.; The use of plant-derived ribosome inactivating proteins in immunotoxin development: past, present and future generations. Toxins (Basel) 2017,9(11),9","journal-title":"Toxins (Basel)"},{"key":"ref=101","first-page":"947","volume":"47","author":"Blakey D.C.","year":"1987","unstructured":"Blakey D.C.; Watson G.J.; Knowles P.P.; Thorpe P.E.; Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody. Cancer Res 1987,47(4),947-952","journal-title":"Cancer Res"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/toxins12030167","volume":"12","author":"Lu J-Q.","year":"2020","unstructured":"Lu J-Q.; Zhu Z-N.; Zheng Y-T.; Shaw P-C.; Engineering of ribosome-inactivating proteins for improving pharmacological properties. Toxins (Basel) 2020,12(3),12","journal-title":"Toxins (Basel)"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/CJI.0b013e3181a6981c","volume":"32","author":"Cizeau J.","year":"2009","unstructured":"Cizeau J.; Grenkow D.M.; Brown J.G.; Entwistle J.; MacDonald G.C.; Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. J Immunother 2009,32(6),574-584","journal-title":"J Immunother"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1073\/pnas.1405153111","author":"Mazor R.","year":"2014","unstructured":"Mazor R.; Eberle J.A.; Hu X.; Vassall A.N.; Onda M.; Beers R.; Lee E.C.; Kreitman R.J.; Lee B.; Baker D.; King C.; Hassan R.; Benhar I.; Pastan I.; Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. Proceedings of the National Academy of Sciences 2014,111","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1073\/pnas.1815087116","author":"Cheung L.S.","year":"2019","unstructured":"Cheung L.S.; Fu J.; Kumar P.; Kumar A.; Urbanowski M.E.; Ihms E.A.; Parveen S.; Bullen C.K.; Patrick G.J.; Harrison R.; Murphy J.R.; Pardoll D.M.; Bishai W.R.; Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti\u2013PD-1 in melanoma. Proceedings of the National Academy of Sciences 2019,116","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/biomedicines7020038","volume":"7","author":"Zuppone S.","year":"2019","unstructured":"Zuppone S.; Fabbrini M.S.; Vago R.; Hosts for Hostile Protein Production: The Challenge of Recombinant Immunotoxin Expression. Biomedicines 2019,7(2),7","journal-title":"Biomedicines"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","volume":"19","author":"Olsen E.","year":"2001","unstructured":"Olsen E.; Duvic M.; Frankel A.; Kim Y.; Martin A.; Vonderheid E.; Jegasothy B.; Wood G.; Gordon M.; Heald P.; Oseroff A.; Pinter-Brown L.; Bowen G.; Kuzel T.; Fivenson D.; Foss F.; Glode M.; Molina A.; Knobler E.; Stewart S.; Cooper K.; Stevens S.; Craig F.; Reuben J.; Bacha P.; Nichols J.; Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001,19(2),376-388","journal-title":"J Clin Oncol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1158\/1078-0432.CCR-19-2329","volume":"26","author":"Jen E.Y.","year":"2020","unstructured":"Jen E.Y.; Gao X.; Li L.; Zhuang L.; Simpson N.E.; Aryal B.; Wang R.; Przepiorka D.; Shen Y.L.; Leong R.; Liu C.; Sheth C.M.; Bowen S.; Goldberg K.B.; Farrell A.T.; Blumenthal G.M.; Pazdur R.; FDA Approval summary: tagraxofusperzs for treatment of blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res 2020,26(3),532-536","journal-title":"Clin Cancer Res"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","volume":"32","author":"Kreitman R.J.","year":"2018","unstructured":"Kreitman R.J.; Dearden C.; Zinzani P.L.; Delgado J.; Karlin L.; Robak T.; Gladstone D.E.; le Coutre P.; Dietrich S.; Gotic M.; Larratt L.; Offner F.; Schiller G.; Swords R.; Bacon L.; Bocchia M.; Bouabdallah K.; Breems D.A.; Cortelezzi A.; Dinner S.; Doubek M.; Gjertsen B.T.; Gobbi M.; Hellmann A.; Lepretre S.; Maloisel F.; Ravandi F.; Rousselot P.; Rummel M.; Siddiqi T.; Tadmor T.; Troussard X.; Yi C.A.; Saglio G.; Roboz G.J.; Balic K.; Standifer N.; He P.; Marshall S.; Wilson W.; Pastan I.; Yao N-S.; Giles F.; Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia. Leukemia 2018,32(8),1768-1777","journal-title":"Leukemia"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1073\/pnas.1717063115","author":"Mazor R.","year":"2018","unstructured":"Mazor R.; King E.M.; Onda M.; Cuburu N.; Addissie S.; Crown D.; Liu X-F.; Kishimoto T.K.; Pastan I.; Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity. Proceedings of the National Academy of Sciences 2018,115","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"26648","DOI":"10.1021\/acsami.7b05292","volume":"9","author":"Tang Y.","year":"2017","unstructured":"Tang Y.; Liang J.; Wu A.; Chen Y.; Zhao P.; Lin T.; Zhang M.; Xu Q.; Wang J.; Huang Y.; Co-delivery of trichosanthin and albendazole by nano-self-assembly for overcoming tumor multidrug-resistance and metastasis. ACS Appl Mater Interfaces 2017,9(32),26648-26664","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.xphs.2019.10.037","volume":"109","author":"Kim J-S.","year":"2020","unstructured":"Kim J-S.; Jun S-Y.; Kim Y-S.; Critical Issues in the Development of Immunotoxins for Anticancer Therapy. J Pharm Sci 2020,109(1),104-115","journal-title":"J Pharm Sci"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.3389\/fimmu.2019.02626","volume":"10","author":"Gotte G.","year":"2019","unstructured":"Gotte G.; Menegazzi M.; Biological activities of secretory rnases: focus on their oligomerization to design antitumor drugs. Front Immunol 2019,10,2626","journal-title":"Front Immunol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2174\/138920108784567254","volume":"9","author":"De Lorenzo C.","year":"2008","unstructured":"De Lorenzo C.; D\u2019Alessio G.; From immunotoxins to immunoRNases. Curr Pharm Biotechnol 2008,9(3),210-214","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1517\/14712590802631862","volume":"9","author":"Schirrmann T.","year":"2009","unstructured":"Schirrmann T.; Krauss J.; Arndt M.A.; Rybak S.M.; D&#xFC;bel S.; Targeted therapeutic RNases (ImmunoRNases). Expert Opin Biol Ther 2009,9(1),79-95","journal-title":"Expert Opin Biol Ther"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/biomedicines6010028","volume":"6","author":"Jordaan S.","year":"2018","unstructured":"Jordaan S.; Akinrinmade O.A.; Nachreiner T.; Cremer C.; Naran K.; Chetty S.; Barth S.; Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells. Biomedicines 2018,6(1),6","journal-title":"Biomedicines"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2165\/00063030-200822010-00006","volume":"22","author":"Lee J.E.","year":"2008","unstructured":"Lee J.E.; Raines R.T.; Ribonucleases as novel chemotherapeutics: The ranpirnase example. BioDrugs 2008,22(1),53-58","journal-title":"BioDrugs"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/07357900500283143","volume":"23","author":"Costanzi J.","year":"2005","unstructured":"Costanzi J.; Sidransky D.; Navon A.; Goldsweig H.; Ribonucleases as a novel pro-apoptotic anticancer strategy: Review of the preclinical and clinical data for ranpirnase. Cancer Invest 2005,23(7),643-650","journal-title":"Cancer Invest"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2329-6674.1000162]","volume":"6","author":"Kanwar S.S.","year":"2017","unstructured":"Kanwar S.S.; Kumar K.; Ribonuclease as anticancer therapeutics. Enz Eng 2017,6,1","journal-title":"Enz Eng"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3851\/IMP3133","volume":"22","author":"Squiquera L.","year":"2017","unstructured":"Squiquera L.; Taxman D.J.; Brendle S.A.; Torres R.; Sulley J.; Hodge T.; Christensen N.; Sidransky D.; Ranpirnase eradicates human papillomavirus in cultured cells and heals anogenital warts in a Phase I study. Antivir Ther 2017,22(3),247-255","journal-title":"Antivir Ther"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"20783","DOI":"10.1074\/jbc.271.34.20783","volume":"271","author":"Saxena S.K.","year":"1996","unstructured":"Saxena S.K.; Gravell M.; Wu Y-N.; Mikulski S.M.; Shogen K.; Ardelt W.; Youle R.J.; Inhibition of HIV-1 production and selective degradation of viral RNA by an amphibian ribonuclease. J Biol Chem 1996,271(34),20783-20788","journal-title":"J Biol Chem"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1089\/aid.2017.0308","volume":"34","author":"Brand R.M.","year":"2018","unstructured":"Brand R.M.; Siegel A.; Myerski A.; Metter E.J.; Engstrom J.; Brand R.E.; Squiquera L.; Hodge T.; Sulley J.; Cranston R.D.; McGowan I.; Ranpirnase Reduces HIV-1 Infection and Associated Inflammatory Changes in a Human Colorectal Explant Model. AIDS Res Hum Retroviruses 2018,34(10),838-848","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.antiviral.2016.06.009","volume":"132","author":"Hodge T.","year":"2016","unstructured":"Hodge T.; Draper K.; Brasel T.; Freiberg A.; Squiquera L.; Sidransky D.; Sulley J.; Taxman D.J.; Antiviral effect of ranpirnase against Ebola virus. Antiviral Res 2016,132,210-218","journal-title":"Antiviral Res"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12967-020-02376-y","volume":"18","author":"Hauge A.","year":"2020","unstructured":"Hauge A.; Rofstad E.K.; Antifibrotic therapy to normalize the tumor microenvironment. J Transl Med 2020,18(1),207","journal-title":"J Transl Med"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3390\/cancers4030873","volume":"4","author":"Kultti A.","year":"2012","unstructured":"Kultti A.; Li X.; Jiang P.; Thompson C.B.; Frost G.I.; Shepard H.M.; Therapeutic targeting of hyaluronan in the tumor stroma. Cancers (Basel) 2012,4(3),873-903","journal-title":"Cancers (Basel)"},{"key":"ref=126","first-page":"156","author":"Auvinen P.","year":"2000","unstructured":"Auvinen P.; Tammi R.; Parkkinen J.; Tammi M.; &#xC5;gren U.; Johansson R.; Hirvikoski P.; Eskelinen M.; Kosma V-M.; Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 2000,156","journal-title":"Am J Pathol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1111\/j.1742-4658.2010.07800.x","volume":"277","author":"Theocharis A.D.","year":"2010","unstructured":"Theocharis A.D.; Skandalis S.S.; Tzanakakis G.N.; Karamanos N.K.; Proteoglycans in health and disease: Novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 2010,277(19),3904-3923","journal-title":"FEBS J"},{"key":"ref=128","first-page":"21","author":"Provenzano P.P.","year":"2012","unstructured":"Provenzano P.P.; Cuevas C.; Chang A.E.; Goel V.K.; Von Hoff D.D.; Hingorani S.R.; Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012,21","journal-title":"Cancer Cell"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/B978-0-12-800092-2.00013-7","volume":"123","author":"Grass G.D.","year":"2014","unstructured":"Grass G.D.; Dai L.; Qin Z.; Parsons C.; Toole B.P.; CD147: Regulator of hyaluronan signaling in invasiveness and chemoresistance. Adv Cancer Res 2014,123,351-373","journal-title":"Adv Cancer Res"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3389\/fonc.2015.00192","volume":"5","author":"Shepard H.M.","year":"2015","unstructured":"Shepard H.M.; Breaching the castle walls: hyaluronan depletion as a therapeutic approach to cancer therapy. Front Oncol 2015,5,192","journal-title":"Front Oncol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1177\/1078155218817819","volume":"25","author":"de Lemos M.L.","year":"2019","unstructured":"de Lemos M.L.; Dar Santos A.; Clinical considerations of hyaluronidase as an adjunct to subcutaneous rituximab injection. J Oncol Pharm Pract 2019,25(4),964-965","journal-title":"J Oncol Pharm Pract"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1177\/1060028019877936","volume":"54","author":"Duco M.R.","year":"2020","unstructured":"Duco M.R.; Murdock J.L.; Reeves D.J.; Trastuzumab\/hyaluronidase-oysk: a new option for patients with HER2-positive breast cancer. Ann Pharmacother 2020,54(3),254-261","journal-title":"Ann Pharmacother"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s11523-019-00684-y","volume":"14","author":"Heo Y-A.","year":"2019","unstructured":"Heo Y-A.; Syed Y.Y.; Subcutaneous trastuzumab: a review in HER2-positive breast cancer. Target Oncol 2019,14(6),749-758","journal-title":"Target Oncol"},{"key":"ref=134","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3474","author":"Gao J.J.","year":"2020","unstructured":"Gao J.J.; Osgood C.L.; Gong Y.; Zhang H.; Bloomquist E.W.; Jiang X.; Qiu J.; Yu J.; Song P.; Rahman A.; Chiu H-J.; Ricks T.K.; Rizvi F.; Hou S.; Wilson W.; Abukhdeir A.M.; Seidman J.; Ghosh S.; Philip R.; Pierce W.F.; Bhatnagar V.; Kluetz P.G.; Pazdur R.; Beaver J.A.; Amiri-Kordestani L.; FDA approval summary: pertuzumab, trastuzumab, and hyaluronidase-zzxf injection for subcutaneous use in patients with HER2-positive breast cancer. Clin Cancer Res 2020","journal-title":"Clin Cancer Res"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s40265-020-01385-x","volume":"80","author":"Lamb Y.N.","year":"2020","unstructured":"Lamb Y.N.; Daratumumab: a review in combination therapy for transplant-eligible newly diagnosed multiple myeloma. Drugs 2020,80(14),1455-1464","journal-title":"Drugs"},{"key":"ref=136","first-page":"175","author":"Maneval D.C.","year":"2020","unstructured":"Maneval D.C.; Caster L.; Derunes C.; Locke K.W.; Muhsin M.; Sauter S.; Sekulovich R.E.; Thompson C.B.; LaBarre M.J.; Pegvorhyaluronidase alfa: A PEGylated recombinant human hyaluronidase PH20 for the treatment of cancers that accumulate hyaluronan 2020,175-204","journal-title":"Pegvorhyaluronidase alfa: A PEGylated recombinant human hyaluronidase PH20 for the treatment of cancers that accumulate hyaluronan"},{"key":"ref=137","first-page":"118","author":"Infante J.R.","year":"2018","unstructured":"Infante J.R.; Korn R.L.; Rosen L.S.; LoRusso P.; Dychter S.S.; Zhu J.; Maneval D.C.; Jiang P.; Shepard H.M.; Frost G.; Von Hoff D.D.; Borad M.J.; Ramanathan R.K.; Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. Br J Cancer 2018,118","journal-title":"Br J Cancer"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","volume":"36","author":"Hingorani S.R.","year":"2018","unstructured":"Hingorani S.R.; Zheng L.; Bullock A.J.; Seery T.E.; Harris W.P.; Sigal D.S.; Braiteh F.; Ritch P.S.; Zalupski M.M.; Bahary N.; Oberstein P.E.; Wang-Gillam A.; Wu W.; Chondros D.; Jiang P.; Khelifa S.; Pu J.; Aldrich C.; Hendifar A.E.; HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel\/Gemcitabine Versus Nab-Paclitaxel\/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. J Clin Oncol 2018,36(4),359-366","journal-title":"J Clin Oncol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2217\/fon-2017-0338","volume":"14","author":"Doherty G.J.","year":"2018","unstructured":"Doherty G.J.; Tempero M.; Corrie P.G.; HALO-109-301: A Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. Future Oncol 2018,14(1),13-22","journal-title":"Future Oncol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11912-017-0608-3","volume":"19","author":"Wong K.M.","year":"2017","unstructured":"Wong K.M.; Horton K.J.; Coveler A.L.; Hingorani S.R.; Harris W.P.; Targeting the Tumor Stroma: The Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20). Curr Oncol Rep 2017,19(7),47","journal-title":"Curr Oncol Rep"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1021\/acs.molpharmaceut.0c00294","volume":"17","author":"Soundararajan R.","year":"2020","unstructured":"Soundararajan R.; Wang G.; Petkova A.; Uchegbu I.F.; Sch&#xE4;tzlein A.G.; Hyaluronidase coated molecular envelope technology nanoparticles enhance drug absorption via the subcutaneous route. Mol Pharm 2020,17(7),2599-2611","journal-title":"Mol Pharm"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"9690","DOI":"10.1039\/c3nr02787b","volume":"5","author":"Scodeller P.","year":"2013","unstructured":"Scodeller P.; Catalano P.N.; Salguero N.; Duran H.; Wolosiuk A.; Soler-Illia G.J.A.A.; Hyaluronan degrading silica nanoparticles for skin cancer therapy. Nanoscale 2013,5(20),9690-9698","journal-title":"Nanoscale"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1021\/acs.nanolett.6b00820","volume":"16","author":"Zhou H.","year":"2016","unstructured":"Zhou H.; Fan Z.; Deng J.; Lemons P.K.; Arhontoulis D.C.; Bowne W.B.; Cheng H.; Hyaluronidase embedded in nanocarrier PEG shell for enhanced tumor penetration and highly efficient antitumor efficacy. Nano Lett 2016,16(5),3268-3277","journal-title":"Nano Lett"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.7150\/thno.15095","volume":"6","author":"Zhou H.","year":"2016","unstructured":"Zhou H.; Fan Z.; Lemons P.K.; Cheng H.; A facile approach to functionalize cell membrane-coated nanoparticles. Theranostics 2016,6(7),1012-1022","journal-title":"Theranostics"},{"key":"ref=145","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-020-01264-9","author":"Kim S.S.","year":"2020","unstructured":"Kim S.S.; Kim H.K.; Kim H.; Lee W.T.; Lee E.S.; Oh K.T.; Choi H-G.; Youn Y.S.; Hyperthermal paclitaxel-bound albumin nanoparticles co-loaded with indocyanine green and hyaluronidase for treating pancreatic cancers. Arch Pharm Res 2020","journal-title":"Arch Pharm Res"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1080\/21691401.2018.1470528","volume":"46","author":"Dai J.","year":"2018","unstructured":"Dai J.; Han S.; Ju F.; Han M.; Xu L.; Zhang R.; Sun Y.; Preparation and evaluation of tumour microenvironment response multistage nanoparticles for epirubicin delivery and deep tumour penetrationArtif Cells Nanomed Biotechnol, 2018,46(sup2),860-873","journal-title":"Preparation and evaluation of tumour microenvironment response multistage nanoparticles for epirubicin delivery and deep tumour penetrationArtif Cells Nanomed Biotechnol,"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0378-1119(91)90622-I","volume":"109","author":"Yeldandi A.V.","year":"1991","unstructured":"Yeldandi A.V.; Yeldandi V.; Kumar S.; Murthy C.V.; Wang X.D.; Alvares K.; Rao M.S.; Reddy J.K.; Molecular evolution of the urate oxidase-encoding gene in hominoid primates: Nonsense mutations. Gene 1991,109(2),281-284","journal-title":"Gene"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2147\/OTT.S103864","volume":"10","author":"Alakel N.","year":"2017","unstructured":"Alakel N.; Middeke J.M.; Schetelig J.; Bornh&#xE4;user M.; Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase. OncoTargets Ther 2017,10,597-605","journal-title":"OncoTargets Ther"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1042\/BA20010083","volume":"36","author":"Bayol A.","year":"2002","unstructured":"Bayol A.; Capdevielle J.; Malazzi P.; Buzy A.; Claude Bonnet M.; Colloc\u2019h N.; Mornon J-P.; Loyaux D.; Ferrara P.; Modification of a reactive cysteine explains differences between rasburicase and Uricozyme, a natural Aspergillus flavus uricase. Biotechnol Appl Biochem 2002,36(1),21-31","journal-title":"Biotechnol Appl Biochem"},{"key":"ref=150","volume":"22","author":"Owens R.E.","year":"2016","unstructured":"Owens R.E.; Swanson H.; Twilla J.D.; Hemolytic anemia induced by pegloticase infusion in a patient with G6PD deficiencyJCR: Journal of Clinical Rheumatology 2016,22","journal-title":"Hemolytic anemia induced by pegloticase infusion in a patient with G6PD deficiencyJCR: Journal of Clinical Rheumatology"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1200\/JCO.2001.19.3.697","volume":"19","author":"Pui C-H.","year":"2001","unstructured":"Pui C-H.; Mahmoud H.H.; Wiley J.M.; Woods G.M.; Leverger G.; Camitta B.; Hastings C.; Blaney S.M.; Relling M.V.; Reaman G.H.; Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. J Clin Oncol 2001,19(3),697-704","journal-title":"J Clin Oncol"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.addr.2007.06.011","volume":"60","author":"Sherman M.R.","year":"2008","unstructured":"Sherman M.R.; Saifer M.G.P.; Perez-Ruiz F.; PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008,60(1),59-68","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1073\/pnas.1001072107","author":"Hershfield M.S.","year":"2010","unstructured":"Hershfield M.S.; Roberts L.J.; Ganson N.J.; Kelly S.J.; Santisteban I.; Scarlett E.; Jaggers D.; Sundy J.S.; Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci 2010,107","journal-title":"Proc Natl Acad Sci"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.semarthrit.2020.04.011","volume":"50","author":"Schlesinger N.","year":"2020","unstructured":"Schlesinger N.; Lipsky P.E.; Pegloticase treatment of chronic refractory gout: Update on efficacy and safety. Semin Arthritis Rheum 2020,50(3S),S31-S38","journal-title":"Semin Arthritis Rheum"},{"key":"ref=155","first-page":"90","volume":"9","author":"Najjari A.","year":"2020","unstructured":"Najjari A.; Rahimi H.; Nojoumi S.A.; Omidinia E.; Computational approach for rational design of fusion uricase with PAS sequences. Int J Mol Cell Med 2020,9(1),90-103","journal-title":"Int J Mol Cell Med"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jconrel.2013.06.037","volume":"171","author":"Geraths C.","year":"2013","unstructured":"Geraths C.; Daoud-El Baba M.; Charpin-El Hamri G.; Weber W.; A biohybrid hydrogel for the urate-responsive release of urate oxidase. J Control Release 2013,171(1),57-62","journal-title":"J Control Release"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"20255","DOI":"10.1021\/acsami.5b05758","volume":"7","author":"Xiong H.","year":"2015","unstructured":"Xiong H.; Zhou Y.; Zhou Q.; He D.; Wan S.; Tan Q.; Zhang M.; Deng X.; Zhang J.; Nanosomal microassemblies for highly efficient and safe delivery of therapeutic enzymes. ACS Appl Mater Interfaces 2015,7(36),20255-20263","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.colsurfb.2010.05.006","volume":"79","author":"Yoshimoto M.","year":"2010","unstructured":"Yoshimoto M.; Takaki N.; Yamasaki M.; Catalase-conjugated liposomes encapsulating glucose oxidase for controlled oxidation of glucose with decomposition of hydrogen peroxide produced. Colloids Surf B Biointerfaces 2010,79(2),403-408","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"20136","DOI":"10.1038\/srep20136","volume":"7","author":"Zhou Y.","year":"2016","unstructured":"Zhou Y.; Zhang M.; He D.; Hu X.; Xiong H.; Wu J.; Zhu B.; Zhang J.; Uricase alkaline enzymosomes with enhanced stabilities and anti-hyperuricemia effects induced by favorable microenvironmental changes. Sci Rep 2016,7,20136","journal-title":"Sci Rep"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"44330","DOI":"10.1038\/srep44330","volume":"7","author":"Jung S.","year":"2017","unstructured":"Jung S.; Kwon I.; Synergistic degradation of a hyperuricemia-causing metabolite using one-pot enzyme-nanozyme cascade reactions. Sci Rep 2017,7,44330","journal-title":"Sci Rep"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jconrel.2019.07.038","volume":"309","author":"Kim S.","year":"2019","unstructured":"Kim S.; Kim M.; Jung S.; Kwon K.; Park J.; Kim S.; Kwon I.; Tae G.; Co-delivery of therapeutic protein and catalase-mimic nanoparticle using a biocompatible nanocarrier for enhanced therapeutic effect. J Control Release 2019,309,181-189","journal-title":"J Control Release"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1128\/jb.156.3.1222-1227.1983","volume":"156","author":"Minton N.P.","year":"1983","unstructured":"Minton N.P.; Atkinson T.; Sherwood R.F.; Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia coli and Pseudomonas putida. J Bacteriol 1983,156(3),1222-1227","journal-title":"J Bacteriol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"7207","DOI":"10.1016\/S0021-9258(19)45873-0","volume":"246","author":"McCullough J.L.","year":"1971","unstructured":"McCullough J.L.; Chabner B.A.; Bertino J.R.; Purification and properties of carboxypeptidase G 1. J Biol Chem 1971,246(23),7207-7213","journal-title":"J Biol Chem"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1432-1033.1985.tb08860.x","volume":"148","author":"Sherwood R.F.","year":"1985","unstructured":"Sherwood R.F.; Melton R.G.; Alwan S.M.; Hughes P.; Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method. Eur J Biochem 1985,148(3),447-453","journal-title":"Eur J Biochem"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S0969-2126(97)00191-3","volume":"5","author":"Rowsell S.","year":"1997","unstructured":"Rowsell S.; Pauptit R.A.; Tucker A.D.; Melton R.G.; Blow D.M.; Brick P.; Crystal structure of carboxypeptidase G2, a bacterial enzyme with applications in cancer therapy. Structure 1997,5(3),337-347","journal-title":"Structure"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/TCRM.S30135","volume":"8","author":"Green J.M.","year":"2012","unstructured":"Green J.M.; Glucarpidase to combat toxic levels of methotrexate in patients. Ther Clin Risk Manag 2012,8,403-413","journal-title":"Ther Clin Risk Manag"},{"key":"ref=167","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108725","volume":"112","author":"Al-Qahtani A.D.","year":"2019","unstructured":"Al-Qahtani A.D.; Bashraheel S.S.; Rashidi F.B.; O\u2019Connor C.D.; Romero A.R.; Domling A.; Goda S.K.; Production of &#x201C;biobetter&#x201D; variants of glucarpidase with enhanced enzyme activity. Biomed Pharmacother 2019,112(108725)","journal-title":"Biomed Pharmacother"},{"key":"ref=168","unstructured":"Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_ docs\/label\/2012\/125327lbl.pdf"},{"key":"ref=169","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20205023","volume":"20","author":"Bedoui Y.","year":"2019","unstructured":"Bedoui Y.; Guillot X.; S&#xE9;lambarom J.; Guiraud P.; Giry C.; Jaffar-Bandjee M.C.; Ralandison S.; Gasque P.; Methotrexate an Old Drug with New Tricks. Int J Mol Sci 2019,20(20)","journal-title":"Int J Mol Sci"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","volume":"11","author":"Widemann B.C.","year":"2006","unstructured":"Widemann B.C.; Adamson P.C.; Understanding and managing methotrexate nephrotoxicity. Oncologist 2006,11(6),694-703","journal-title":"Oncologist"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/bjc.1971.38","volume":"25","author":"Hansen H.H.","year":"1971","unstructured":"Hansen H.H.; Selawry O.S.; Holland J.F.; McCall C.B.; The variability of individual tolerance to methotrexate in cancer patients. Br J Cancer 1971,25(2),298-305","journal-title":"Br J Cancer"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/sj.bjc.6602337","volume":"92","author":"Buchen S.","year":"2005","unstructured":"Buchen S.; Ngampolo D.; Melton R.G.; Hasan C.; Zoubek A.; Henze G.; Bode U.; Fleischhack G.; Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer 2005,92(3),480-487","journal-title":"Br J Cancer"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1358\/dot.2012.48.11.1871575","volume":"48","author":"Tuffaha H.W.","year":"2012","unstructured":"Tuffaha H.W.; Al Omar S.; Glucarpidase for the treatment of life-threatening methotrexate overdose. Drugs Today (Barc) 2012,48(11),705-711","journal-title":"Drugs Today (Barc)"},{"key":"ref=174","unstructured":"Available from https:\/\/www.wepclinical.com\/wep-clinical-partners-with-btg-specialty-pharmaceuticals-for-european-supply-of-voraxaze\/"},{"key":"ref=175","first-page":"894","volume":"294","author":"Widemann B.C.","year":"2000","unstructured":"Widemann B.C.; Sung E.; Anderson L.; Salzer W.L.; Balis F.M.; Monitjo K.S.; McCully C.; Hawkins M.; Adamson P.C.; Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid. J Pharmacol Exp Ther 2000,294(3),894-901","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1634\/theoncologist.12-11-1299","volume":"12","author":"Schwartz S.","year":"2007","unstructured":"Schwartz S.; Borner K.; M&#xFC;ller K.; Martus P.; Fischer L.; Korfel A.; Auton T.; Thiel E.; Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. Oncologist 2007,12(11),1299-1308","journal-title":"Oncologist"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1200\/JCO.2009.25.4540","volume":"28","author":"Widemann B.C.","year":"2010","unstructured":"Widemann B.C.; Balis F.M.; Kim A.; Boron M.; Jayaprakash N.; Shalabi A.; O\u2019Brien M.; Eby M.; Cole D.E.; Murphy R.F.; Fox E.; Ivy P.; Adamson P.C.; Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: Clinical and pharmacologic factors affecting outcome. J Clin Oncol 2010,28(25),3979-3986","journal-title":"J Clin Oncol"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1093\/jnci\/djh270","volume":"96","author":"Widemann B.C.","year":"2004","unstructured":"Widemann B.C.; Balis F.M.; Shalabi A.; Boron M.; O\u2019Brien M.; Cole D.E.; Jayaprakash N.; Ivy P.; Castle V.; Muraszko K.; Moertel C.L.; Trueworthy R.; Hermann R.C.; Moussa A.; Hinton S.; Reaman G.; Poplack D.; Adamson P.C.; Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst 2004,96(20),1557-1559","journal-title":"J Natl Cancer Inst"},{"key":"ref=179","unstructured":"Available from https:\/\/www.who.int\/health-topics\/cardiovascular-diseases"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1161\/ATVBAHA.111.230631","volume":"31","author":"Undas A.","year":"2011","unstructured":"Undas A.; Ari&#xEB;ns R.A.S.; Fibrin clot structure and function: A role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011,31(12),e88-e99","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1111\/j.1538-7836.2005.01365.x","volume":"3","author":"Mosesson M.W.","year":"2005","unstructured":"Mosesson M.W.; Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005,3(8),1894-1904","journal-title":"J Thromb Haemost"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.blre.2014.09.003","volume":"29","author":"Chapin J.C.","year":"2015","unstructured":"Chapin J.C.; Hajjar K.A.; Fibrinolysis and the control of blood coagulation. Blood Rev 2015,29(1),17-24","journal-title":"Blood Rev"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.csbj.2019.06.023","volume":"17","author":"Mican J.","year":"2019","unstructured":"Mican J.; Toul M.; Bednar D.; Damborsky J.; Structural biology and protein engineering of thrombolytics. Comput Struct Biotechnol J 2019,17,917-938","journal-title":"Comput Struct Biotechnol J"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1160\/TH04-12-0842","volume":"93","author":"Castellino F.J.","year":"2005","unstructured":"Castellino F.J.; Ploplis V.A.; Structure and function of the plasminogen\/plasmin system. Thromb Haemost 2005,93(4),647-654","journal-title":"Thromb Haemost"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.celrep.2012.02.012","volume":"1","author":"Law R.H.P.","year":"2012","unstructured":"Law R.H.P.; Caradoc-Davies T.; Cowieson N.; Horvath A.J.; Quek A.J.; Encarnacao J.A.; Steer D.; Cowan A.; Zhang Q.; Lu B.G.C.; Pike R.N.; Smith A.I.; Coughlin P.B.; Whisstock J.C.; The X-ray crystal structure of full-length human plasminogen. Cell Rep 2012,1(3),185-190","journal-title":"Cell Rep"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.sbi.2013.10.006","volume":"23","author":"Law R.H.P.","year":"2013","unstructured":"Law R.H.P.; Abu-Ssaydeh D.; Whisstock J.C.; New insights into the structure and function of the plasminogen\/plasmin system. Curr Opin Struct Biol 2013,23(6),836-841","journal-title":"Curr Opin Struct Biol"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/PL00000615","volume":"56","author":"Irigoyen J.P.","year":"1999","unstructured":"Irigoyen J.P.; Mu&#xF1;oz-C&#xE1;noves P.; Montero L.; Koziczak M.; Nagamine Y.; The plasminogen activator system: Biology and regulation. Cell Mol Life Sci 1999,56(1-2),104-132","journal-title":"Cell Mol Life Sci"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1111\/jth.14157","volume":"16","author":"Urano T.","year":"2018","unstructured":"Urano T.; Castellino F.J.; Suzuki Y.; Regulation of plasminogen activation on cell surfaces and fibrin. J Thromb Haemost 2018,16(8),1487-1497","journal-title":"J Thromb Haemost"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"6647","DOI":"10.1007\/s00253-013-5052-1","volume":"97","author":"Kotb E.","year":"2013","unstructured":"Kotb E.; Activity assessment of microbial fibrinolytic enzymes. Appl Microbiol Biotechnol 2013,97(15),6647-6665","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/978-981-13-7709-9_15","volume":"Vol. 1148","author":"Kumar S.S.","year":"2019","unstructured":"Kumar S.S.; Sabu A.; Therapeutic Enzymes: Function and Clinical Implications 2019,Vol. 1148,345-381","journal-title":"Therapeutic Enzymes: Function and Clinical Implications"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1006\/bbrc.1995.2902","volume":"217","author":"Nihalani D.","year":"1995","unstructured":"Nihalani D.; Sahni G.; Streptokinase contains two independent plasminogen-binding sites. Biochem Biophys Res Commun 1995,217(3),1245-1254","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.biotechadv.2003.09.004","volume":"22","author":"Banerjee A.","year":"2004","unstructured":"Banerjee A.; Chisti Y.; Banerjee U.C.; Streptokinase--a clinically useful thrombolytic agent. Biotechnol Adv 2004,22(4),287-307","journal-title":"Biotechnol Adv"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"8879","DOI":"10.1073\/pnas.96.16.8879","volume":"96","author":"Reed G.L.","year":"1999","unstructured":"Reed G.L.; Houng A.K.; Liu L.; Parhami-Seren B.; Matsueda L.H.; Wang S.; Hedstrom L.; A catalytic switch and the conversion of streptokinase to a fibrin-targeted plasminogen activator. Proc Natl Acad Sci USA 1999,96(16),8879-8883","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"24994","DOI":"10.1074\/jbc.M400253200","volume":"279","author":"Sazonova I.Y.","year":"2004","unstructured":"Sazonova I.Y.; Robinson B.R.; Gladysheva I.P.; Castellino F.J.; Reed G.L.; Alpha Domain deletion converts streptokinase into a fibrin-dependent plasminogen activator through mechanisms akin to staphylokinase and tissue plasminogen activator. J Biol Chem 2004,279(24),24994-25001","journal-title":"J Biol Chem"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0167-5273(02)00004-9","volume":"82","author":"Kazmi K.A.","year":"2002","unstructured":"Kazmi K.A.; Perwaiz Iqbal M.; Rahbar A.; Mehboobali N.; Anti-streptokinase titers and response to streptokinase treatment in Pakistani patients. Int J Cardiol 2002,82(3),247-251","journal-title":"Int J Cardiol"},{"key":"ref=196","first-page":"318","volume":"34","author":"Sikri N.","year":"2007","unstructured":"Sikri N.; Bardia A.; A history of streptokinase use in acute myocardial infarction. Tex Heart Inst J 2007,34(3),318-327","journal-title":"Tex Heart Inst J"},{"key":"ref=197","first-page":"871","volume":"2","year":"1987","unstructured":"(GISSI), G.I.p.l.S.d.S.n.I.M., Long-term effects of intravenous thrombolysis in acute myocardial infarction: Final report of the GISSI study. Lancet 1987,2,871-874","journal-title":"Lancet"},{"key":"ref=198","unstructured":"Available from https:\/\/www.medicines.org.uk\/emc\/product\/4255\/smpc"},{"key":"ref=199","unstructured":"Available from https:\/\/www.medicines.org.uk\/emc\/product\/4256\/smpc"},{"key":"ref=200","unstructured":"Available from www.medicines.org.uk\/emc\/product\/264\/smpc"},{"key":"ref=201","unstructured":"Available from https:\/\/www.medicines.org.uk\/emc\/product\/898\/smpc"},{"key":"ref=202","unstructured":"Available from https:\/\/www.medicines.org.uk\/emc\/product\/3013\/smpc"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/14740338.2019.1573985","volume":"18","author":"Chester K.W.","year":"2019","unstructured":"Chester K.W.; Corrigan M.; Schoeffler J.M.; Shah M.; Toy F.; Purdon B.; Dillon G.M.; Making a case for the right '-ase\u2019 in acute ischemic stroke: Alteplase, tenecteplase, and reteplase. Expert Opin Drug Saf 2019,18(2),87-96","journal-title":"Expert Opin Drug Saf"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/290505a0","volume":"290","author":"Smith R.A.G.","year":"1981","unstructured":"Smith R.A.G.; Dupe R.J.; English P.D.; Green J.; Fibrinolysis with acyl-enzymes: A new approach to thrombolytic therapy. Nature 1981,290(5806),505-508","journal-title":"Nature"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"V3","DOI":"10.1002\/clc.4960131303","volume":"13","author":"Sherry S.","year":"1990","unstructured":"Sherry S.; Pharmacology of anistreplase. Clin Cardiol 1990,13(3)(Suppl. 5),V3-V10","journal-title":"Clin Cardiol"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/21655979.2016.1229718","volume":"8","year":"2017","unstructured":"Adivitiya; Khasa, Y.P. The evolution of recombinant thrombolytics: Current status and future directions. Bioengineered 2017,8(4),331-358","journal-title":"Bioengineered"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/159779a0","volume":"159","author":"MacFarlane R.G.","year":"1947","unstructured":"MacFarlane R.G.; Pilling J.; Fibrinolytic activity of normal urine. Nature 1947,159(4049),779","journal-title":"Nature"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.biocel.2006.10.008","volume":"39","author":"Crippa M.P.","year":"2007","unstructured":"Crippa M.P.; Urokinase-type plasminogen activator. Int J Biochem Cell Biol 2007,39(4),690-694","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/nrm977","volume":"3","author":"Blasi F.","year":"2002","unstructured":"Blasi F.; Carmeliet P.; uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002,3(12),932-943","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1749-6632.1987.tb36247.x","volume":"511","author":"Appella E.","year":"1987","unstructured":"Appella E.; Blasi F.; The growth factor module of urokinase is the binding sequence for its receptor. Ann N Y Acad Sci 1987,511,192-195","journal-title":"Ann N Y Acad Sci"},{"key":"ref=211","first-page":"143","volume":"376","author":"Conese M.","year":"1995","unstructured":"Conese M.; Blasi F.; Urokinase\/urokinase receptor system: Internalization\/degradation of urokinase-serpin complexes: Mechanism and regulation. Biol Chem Hoppe Seyler 1995,376(3),143-155","journal-title":"Biol Chem Hoppe Seyler"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10557-019-06923-8","volume":"33","author":"Gurewich V.","year":"2019","unstructured":"Gurewich V.; Fibrinolysis: a misunderstood natural defense whose therapeutic potential is unknown. Cardiovasc Drugs Ther 2019,33(6),749-753","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10571-019-00737-w","volume":"40","author":"Kadir R.R.A.","year":"2020","unstructured":"Kadir R.R.A.; Bayraktutan U.; Urokinase plasminogen activator: a potential thrombolytic agent for ischaemic stroke. Cell Mol Neurobiol 2020,40(3),347-355","journal-title":"Cell Mol Neurobiol"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/159681b0","volume":"159","author":"Astrup T.","year":"1947","unstructured":"Astrup T.; Permin P.M.; Fibrinolysis in the animal organism. Nature 1947,159(4046),681-682","journal-title":"Nature"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/170929a0","volume":"170","author":"Astrup T.","year":"1952","unstructured":"Astrup T.; Stage A.; Isolation of a soluble fibrinolytic activator from animal tissue. Nature 1952,170(4335),929","journal-title":"Nature"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1161\/ATVBAHA.108.179655","volume":"29","author":"Collen D.","year":"2009","unstructured":"Collen D.; Lijnen H.R.; The tissue-type plasminogen activator story. Arterioscler Thromb Vasc Biol 2009,29(8),1151-1155","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1182\/blood.V73.7.1842.1842","volume":"73","author":"Larsen G.R.","year":"1989","unstructured":"Larsen G.R.; Metzger M.; Henson K.; Blue Y.; Horgan P.; Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. Blood 1989,73(7),1842-1850","journal-title":"Blood"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1172\/JCI118105","volume":"96","author":"Narita M.","year":"1995","unstructured":"Narita M.; Bu G.; Herz J.; Schwartz A.L.; Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. J Clin Invest 1995,96(2),1164-1168","journal-title":"J Clin Invest"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1055\/s-0038-1646377","volume":"66","author":"Lijnen H.R.","year":"1991","unstructured":"Lijnen H.R.; Collen D.; Strategies for the improvement of thrombolytic agents. Thromb Haemost 1991,66(1),88-110","journal-title":"Thromb Haemost"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/301214a0","volume":"301","author":"Pennica D.","year":"1983","unstructured":"Pennica D.; Holmes W.E.; Kohr W.J.; Harkins R.N.; Vehar G.A.; Ward C.A.; Bennett W.F.; Yelverton E.; Seeburg P.H.; Heyneker H.L.; Goeddel D.V.; Collen D.; Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1983,301(5897),214-221","journal-title":"Nature"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","volume":"359","author":"Hacke W.","year":"2008","unstructured":"Hacke W.; Kaste M.; Bluhmki E.; Brozman M.; D&#xE1;valos A.; Guidetti D.; Larrue V.; Lees K.R.; Medeghri Z.; Machnig T.; Schneider D.; von Kummer R.; Wahlgren N.; Toni D.; Investigators E.; Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008,359(13),1317-1329","journal-title":"N Engl J Med"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/ncpneuro0993","volume":"5","author":"Leung T.W.H.","year":"2009","unstructured":"Leung T.W.H.; Wong K.S.L.; Thrombolysis with alteplase for acute ischemic stroke: Safe and effective outside the 3-hour time window? Nat Clin Pract Neurol 2009,5(2),70-71","journal-title":"Nat Clin Pract Neurol"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13017-020-00305-4","volume":"15","author":"Choudhury R.","year":"2020","unstructured":"Choudhury R.; Barrett C.D.; Moore H.B.; Moore E.E.; McIntyre R.C.; Moore P.K.; Talmor D.S.; Nydam T.L.; Yaffe M.B.; Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: A Markov decision analysis. World J Emerg Surg 2020,15(1),29","journal-title":"World J Emerg Surg"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/phar.2465","volume":"40","author":"Dobesh P.P.","year":"2020","unstructured":"Dobesh P.P.; Trujillo T.C.; Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19. Pharmacotherapy 2020,40(11),1130-1151","journal-title":"Pharmacotherapy"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/bjh.16727","volume":"189","author":"Kollias A.","year":"2020","unstructured":"Kollias A.; Kyriakoulis K.G.; Dimakakos E.; Poulakou G.; Stergiou G.S.; Syrigos K.; Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action. Br J Haematol 2020,189(5),846-847","journal-title":"Br J Haematol"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jacc.2020.05.001","volume":"76","author":"Paranjpe I.","year":"2020","unstructured":"Paranjpe I.; Fuster V.; Lala A.; Russak A.J.; Glicksberg B.S.; Levin M.A.; Charney A.W.; Narula J.; Fayad Z.A.; Bagiella E.; Zhao S.; Nadkarni G.N.; Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol 2020,76(1),122-124","journal-title":"J Am Coll Cardiol"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1007\/s00134-020-06141-z","volume":"46","author":"Horie S.","year":"2020","unstructured":"Horie S.; McNicholas B.; Rezoagli E.; Pham T.; Curley G.; McAuley D.; O\u2019Kane C.; Nichol A.; Dos Santos C.; Rocco P.R.M.; Bellani G.; Laffey J.G.; Emerging pharmacological therapies for ARDS: COVID-19 and beyond. Intensive Care Med 2020,46(12),2265-2283","journal-title":"Intensive Care Med"},{"key":"ref=228","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113487","volume":"9","author":"Ranucci M.","year":"2020","unstructured":"Ranucci M.; Sitzia C.; Baryshnikova E.; Di Dedda U.; Cardani R.; Martelli F.; Corsi Romanelli M.; Covid-19-associated coagulopathy: biomarkers of thrombin generation and fibrinolysis leading the outcome. J Clin Med 2020,9(11)","journal-title":"J Clin Med"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"Zhou F.","year":"2020","unstructured":"Zhou F.; Yu T.; Du R.; Fan G.; Liu Y.; Liu Z.; Xiang J.; Wang Y.; Song B.; Gu X.; Guan L.; Wei Y.; Li H.; Wu X.; Xu J.; Tu S.; Zhang Y.; Chen H.; Cao B.; Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020,395(10229),1054-1062","journal-title":"Lancet"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1055\/s-0040-1713152","volume":"120","author":"Bikdeli B.","year":"2020","unstructured":"Bikdeli B.; Madhavan M.V.; Gupta A.; Jimenez D.; Burton J.R.; Der Nigoghossian C.; Chuich T.; Nouri S.N.; Dreyfus I.; Driggin E.; Sethi S.; Sehgal K.; Chatterjee S.; Ageno W.; Madjid M.; Guo Y.; Tang L.V.; Hu Y.; Bertoletti L.; Giri J.; Cushman M.; Qu&#xE9;r&#xE9; I.; Dimakakos E.P.; Gibson C.M.; Lippi G.; Favaloro E.J.; Fareed J.; Tafur A.J.; Francese D.P.; Batra J.; Falanga A.; Clerkin K.J.; Uriel N.; Kirtane A.; McLintock C.; Hunt B.J.; Spyropoulos A.C.; Barnes G.D.; Eikelboom J.W.; Weinberg I.; Schulman S.; Carrier M.; Piazza G.; Beckman J.A.; Leon M.B.; Stone G.W.; Rosenkranz S.; Goldhaber S.Z.; Parikh S.A.; Monreal M.; Krumholz H.M.; Konstantinides S.V.; Weitz J.I.; Lip G.Y.H.; Global C-T.C.; Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb Haemost 2020,120(7),1004-1024","journal-title":"Thromb Haemost"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/TA.0000000000002694","volume":"88","author":"Moore H.B.","year":"2020","unstructured":"Moore H.B.; Barrett C.D.; Moore E.E.; McIntyre R.C.; Moore P.K.; Talmor D.S.; Moore F.A.; Yaffe M.B.; Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome? J Trauma Acute Care Surg 2020,88(6),713-714","journal-title":"J Trauma Acute Care Surg"},{"key":"ref=232","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/000313480106700417","volume":"67","author":"Hardaway R.M.","year":"2001","unstructured":"Hardaway R.M.; Harke H.; Tyroch A.H.; Williams C.H.; Vazquez Y.; Krause G.F.; Treatment of severe acute respiratory distress syndrome: A final report on a phase I study. Am Surg 2001,67(4),377-382","journal-title":"Am Surg"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1053\/j.jvca.2019.05.035","volume":"34","author":"Abdelaal Ahmed Mahmoud A.","year":"2020","unstructured":"Abdelaal Ahmed Mahmoud A.; Mahmoud H.E.; Mahran M.A.; Khaled M.; Streptokinase Versus Unfractionated heparin nebulization in patients with severe acute respiratory distress syndrome (ARDS): a randomized controlled trial with observational controls. J Cardiothorac Vasc Anesth 2020,34(2),436-443","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"ref=234","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02208-2","author":"Goyal A.","year":"2020","unstructured":"Goyal A.; Saigal S.; Niwariya Y.; Sharma J.; Singh P.; Successful use of tPA for thrombolysis in COVID related ARDS: A case series. J Thromb Thrombolysis 2020","journal-title":"J Thromb Thrombolysis"},{"key":"ref=235","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.44","volume":"10","author":"Poor H.D.","year":"2020","unstructured":"Poor H.D.; Ventetuolo C.E.; Tolbert T.; Chun G.; Serrao G.; Zeidman A.; Dangayach N.S.; Olin J.; Kohli-Seth R.; Powell C.A.; COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis. Clin Transl Med 2020,10(2)","journal-title":"Clin Transl Med"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1111\/jth.14828","volume":"18","author":"Wang J.","year":"2020","unstructured":"Wang J.; Hajizadeh N.; Moore E.E.; McIntyre R.C.; Moore P.K.; Veress L.A.; Yaffe M.B.; Moore H.B.; Barrett C.D.; Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. J Thromb Haemost 2020,18(7),1752-1755","journal-title":"J Thromb Haemost"},{"key":"ref=237","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105201","volume":"29","author":"Carneiro T.","year":"2020","unstructured":"Carneiro T.; Dashkoff J.; Leung L.Y.; Nobleza C.O.S.; Marulanda-Londono E.; Hathidara M.; Koch S.; Sur N.; Boske A.; Voetsch B.; Aboul Nour H.; Miller D.J.; Daneshmand A.; Shulman J.; Curiale G.; Greer D.M.; Romero J.R.; Anand P.; Cervantes-Arslanian A.M.; Intravenous tPA for Acute Ischemic Stroke in Patients with COVID-19. J Stroke Cerebrovasc Dis 2020,29(11)","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1073\/pnas.91.9.3670","volume":"91","author":"Keyt B.A.","year":"1994","unstructured":"Keyt B.A.; Paoni N.F.; Refino C.J.; Berleau L.; Nguyen H.; Chow A.; Lai J.; Pe&#xF1;a L.; Pater C.; Ogez J.; Etcheverry T.; Botstein D.; Bennett W.F.; A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994,91(9),3670-3674","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=239","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1161\/01.CIR.95.2.351","volume":"95","author":"Cannon C.P.","year":"1997","unstructured":"Cannon C.P.; McCabe C.H.; Gibson C.M.; Ghali M.; Sequeira R.F.; McKendall G.R.; Breed J.; Modi N.B.; Fox N.L.; Tracy R.P.; Love T.W.; Braunwald E.; Coulson T.; Mayor M.R.; Girwarr G.; Teixeiro P.; Williams D.O.; McDonald M.; Kirshenbaum J.M.; Cloutier J.; Henry T.D.; Knox L.; Boisjolie C.; Schweiger M.J.; Burkott B.; Warwick D.; Carney R.; Murphy G.; Cutler D.; Malmberg G.; Greene R.M.; Healy E.; Perry V.; Watkins M.; Sobel B.E.; Rowen M.; Wilson W.; Cuttitta J.; Niederman A.; Kellerman T.; Frey M.; Taylor H.; Mueller H.S.; Kunkel L.; Cosico J.; Casale P.; Tuzi J.; Rogers W.J.; Morgan T.; Anderson J.L.; Karagounis L.; Allen A.; Hochman J.S.; McAnulty M.; TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997,95(2),351-356","journal-title":"Circulation"},{"key":"ref=240","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/00001573-199909000-00007","volume":"14","author":"Zeymer U.","year":"1999","unstructured":"Zeymer U.; Neuhaus K.L.; Clinical trials in acute myocardial infarction. Curr Opin Cardiol 1999,14(5),392-402","journal-title":"Curr Opin Cardiol"},{"key":"ref=241","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/protein\/5.1.93","volume":"5","author":"Kohnert U.","year":"1992","unstructured":"Kohnert U.; Rudolph R.; Verheijen J.H.; Weening-Verhoeff E.J.D.; Stern A.; Opitz U.; Martin U.; Lill H.; Prinz H.; Lechner M.; Kresse G.B.; Buckel P.; Fischer S.; Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Protein Eng 1992,5(1),93-100","journal-title":"Protein Eng"},{"key":"ref=242","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1093\/oxfordjournals.eurheartj.a014716","volume":"17","author":"Malcolm A.D.","year":"1996","unstructured":"Malcolm A.D.; Keltai M.; Walsh M.J.; Hennersdorf G.; Dymond D.; Fabian J.; Sochman J.; Bertrand M.; Masquet C.; Letac B.; Bory M.; Eha J.; DeVita C.; Ravazzi P.; Gatto E.; Abbadessa F.; Perrins J.; Walsh M.; Daly K.; ESPRIT: A European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction. Eur Heart J 1996,17(10),1522-1531","journal-title":"Eur Heart J"},{"key":"ref=243","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1055\/s-0038-1646461","volume":"66","author":"Martin U.","year":"1991","unstructured":"Martin U.; von M&#xF6;llendorff E.; Akpan W.; Kientsch-Engel R.; Kaufmann B.; Neugebauer G.; Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers. Thromb Haemost 1991,66(5),569-574","journal-title":"Thromb Haemost"},{"key":"ref=244","first-page":"1087","volume":"28","author":"Oikawa K.","year":"2000","unstructured":"Oikawa K.; Watanabe T.; Higuchi S.; Comparison of drug disposition between wild-type and novel tissue-type plasminogen activator pamiteplase in rats. Drug Metab Dispos 2000,28(9),1087-1093","journal-title":"Drug Metab Dispos"},{"key":"ref=245","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1080\/00498250050200140","volume":"30","author":"Oikawa K.","year":"2000","unstructured":"Oikawa K.; Watanabe T.; Miyamoto I.; Higuchi S.; Determination, pharmacokinetics and protein binding of a novel tissue-type plasminogen activator, pamiteplase in human plasma. Xenobiotica 2000,30(10),993-1003","journal-title":"Xenobiotica"},{"key":"ref=246","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1055\/s-0038-1649569","volume":"70","author":"Agnelli G.","year":"1993","unstructured":"Agnelli G.; Pascucci C.; Nenci G.G.; Mele A.; B&#xFC;rgi R.; Heim J.; Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). Thromb Haemost 1993,70(2),294-300","journal-title":"Thromb Haemost"},{"key":"ref=247","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s11033-019-05167-x","volume":"47","author":"Nedaeinia R.","year":"2020","unstructured":"Nedaeinia R.; Faraji H.; Javanmard S.H.; Ferns G.A.; Ghayour-Mobarhan M.; Goli M.; Mashkani B.; Nedaeinia M.; Haghighi M.H.H.; Ranjbar M.; Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion. Mol Biol Rep 2020,47(1),819-841","journal-title":"Mol Biol Rep"},{"key":"ref=248","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/211434c0","volume":"211","author":"Hawkey C.","year":"1966","unstructured":"Hawkey C.; Plasminogen activator in saliva of the vampire bat Desmodus rotundus. Nature 1966,211(5047),434-435","journal-title":"Nature"},{"key":"ref=249","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0378-1119(91)90155-5","volume":"105","author":"Kr&#xE4;tzschmar J.","year":"1991","unstructured":"Kr&#xE4;tzschmar J.; Haendler B.; Langer G.; Boidol W.; Bringmann P.; Alagon A.; Donner P.; Schleuning W.D.; The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus: Cloning and expression. Gene 1991,105(2),229-237","journal-title":"Gene"},{"key":"ref=250","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1749-6632.1992.tb51639.x","volume":"667","author":"Schleuning W.D.","year":"1992","unstructured":"Schleuning W.D.; Alagon A.; Boidol W.; Bringmann P.; Petri T.; Kr&#xE4;tzschmar J.; Haendler B.; Langer G.; Baldus B.; Witt W.; Donner P.; Plasminogen activators from the saliva of Desmodus rotundus (common vampire bat): Unique fibrin specificity. Ann N Y Acad Sci 1992,667,395-403","journal-title":"Ann N Y Acad Sci"},{"key":"ref=251","doi-asserted-by":"publisher","first-page":"25596","DOI":"10.1074\/jbc.270.43.25596","volume":"270","author":"Bringmann P.","year":"1995","unstructured":"Bringmann P.; Gruber D.; Liese A.; Toschi L.; Kr&#xE4;tzchmar J.; Schleuning W.D.; Donner P.; Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 1995,270(43),25596-25603","journal-title":"J Biol Chem"},{"key":"ref=252","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1476-5381.2011.01514.x","volume":"165","author":"Medcalf R.L.","year":"2012","unstructured":"Medcalf R.L.; Desmoteplase: Discovery, insights and opportunities for ischaemic stroke. Br J Pharmacol 2012,165(1),75-89","journal-title":"Br J Pharmacol"},{"key":"ref=253","first-page":"118","volume":"31","author":"Schleuning W.D.","year":"2001","unstructured":"Schleuning W.D.; Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): A thrombolytic drug optimized by natural selection. Haemostasis 2001,31(3-6),118-122","journal-title":"Haemostasis"},{"key":"ref=254","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(08)70267-9","volume":"8","author":"Hacke W.","year":"2009","unstructured":"Hacke W.; Furlan A.J.; Al-Rawi Y.; Davalos A.; Fiebach J.B.; Gruber F.; Kaste M.; Lipka L.J.; Pedraza S.; Ringleb P.A.; Rowley H.A.; Schneider D.; Schwamm L.H.; Leal J.S.; S&#xF6;hngen M.; Teal P.A.; Wilhelm-Ogunbiyi K.; Wintermark M.; Warach S.; Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): A prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009,8(2),141-150","journal-title":"Lancet Neurol"},{"key":"ref=255","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1161\/STROKEAHA.116.013715","volume":"47","author":"von Kummer R.","year":"2016","unstructured":"von Kummer R.; Mori E.; Truelsen T.; Jensen J.S.; Gr&#xF8;nning B.A.; Fiebach J.B.; Lovblad K.O.; Pedraza S.; Romero J.M.; Chabriat H.; Chang K.C.; D&#xE1;valos A.; Ford G.A.; Grotta J.; Kaste M.; Schwamm L.H.; Shuaib A.; Albers G.W.; Investigators D.; Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke: The DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke). Stroke 2016,47(12),2880-2887","journal-title":"Stroke"},{"key":"ref=256","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nsb0597-357","volume":"4","author":"Rabijns A.","year":"1997","unstructured":"Rabijns A.; De Bondt H.L.; De Ranter C.; Three-dimensional structure of staphylokinase, a plasminogen activator with therapeutic potential. Nat Struct Biol 1997,4(5),357-360","journal-title":"Nat Struct Biol"},{"key":"ref=257","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1538-7836.2009.03701.x","volume":"8","author":"Marder V.J.","year":"2010","unstructured":"Marder V.J.; Novokhatny V.; Direct fibrinolytic agents: Biochemical attributes, preclinical foundation and clinical potential. J Thromb Haemost 2010,8(3),433-444","journal-title":"J Thromb Haemost"},{"key":"ref=258","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/j.1538-7836.2011.04370.x","volume":"9","author":"Marder V.J.","year":"2011","unstructured":"Marder V.J.; Historical perspective and future direction of thrombolysis research: The re-discovery of plasmin. J Thromb Haemost 2011,9(Suppl. 1),364-373","journal-title":"J Thromb Haemost"},{"key":"ref=259","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jvir.2009.03.043","volume":"20","author":"Hoefer I.E.","year":"2009","unstructured":"Hoefer I.E.; Stroes E.S.G.; Pasterkamp G.; Levi M.M.; Reekers J.A.; Verhagen H.J.M.; Meijers J.C.; Humphries J.E.; Rotmans J.I.; Locally applied recombinant plasmin results in effective thrombolysis in a porcine model of arteriovenous graft thrombosis. J Vasc Interv Radiol 2009,20(7),951-958","journal-title":"J Vasc Interv Radiol"},{"key":"ref=260","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/j.1538-7836.2008.02969.x","volume":"6","author":"Shlansky-Goldberg R.D.","year":"2008","unstructured":"Shlansky-Goldberg R.D.; Matsumoto A.H.; Baumbach G.A.; Siegel J.B.; Raabe R.D.; Murphy T.P.; Deng C.; Ray Dawkins J.; Marder V.J.; A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion. J Thromb Haemost 2008,6(6),944-950","journal-title":"J Thromb Haemost"},{"key":"ref=261","doi-asserted-by":"publisher","first-page":"6454","DOI":"10.1039\/C7CS00891K","volume":"47","author":"Fu L.H.","year":"2018","unstructured":"Fu L.H.; Qi C.; Lin J.; Huang P.; Catalytic chemistry of glucose oxidase in cancer diagnosis and treatment. Chem Soc Rev 2018,47(17),6454-6472","journal-title":"Chem Soc Rev"},{"key":"ref=262","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1477-9560-11-2","volume":"11","author":"Lin X.","year":"2013","unstructured":"Lin X.; Wang Y.; Zhang Y.; Huang B.; Lin J.J.; Hallock S.J.; Yu H.; Shao H.; Yan J.; Huang B.; Zhang X.C.J.; Cao W.; Xu X.; Lin X.; Purification and characterization of mutant miniPlasmin for thrombolytic therapy. Thromb J 2013,11(1),2","journal-title":"Thromb J"},{"key":"ref=263","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1046\/j.1538-7836.2003.00078.x","volume":"1","author":"Nagai N.","year":"2003","unstructured":"Nagai N.; Demarsin E.; Van Hoef B.; Wouters S.; Cingolani D.; Laroche Y.; Collen D.; Recombinant human microplasmin: Production and potential therapeutic properties. J Thromb Haemost 2003,1(2),307-313","journal-title":"J Thromb Haemost"},{"key":"ref=264","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1161\/STROKEAHA.109.560201","volume":"40","author":"Thijs V.N.S.","year":"2009","unstructured":"Thijs V.N.S.; Peeters A.; Vosko M.; Aichner F.; Schellinger P.D.; Schneider D.; Neumann-Haefelin T.; R&#xF6;ther J.; Davalos A.; Wahlgren N.; Verhamme P.; Randomized, placebo-controlled, dose-ranging clinical trial of intravenous microplasmin in patients with acute ischemic stroke. Stroke 2009,40(12),3789-3795","journal-title":"Stroke"},{"key":"ref=265","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217234","volume":"14","author":"Kaur N.","year":"2019","unstructured":"Kaur N.; Sinha P.K.; Sahni G.; Site-specific PEGylation of micro-plasmin for improved thrombolytic therapy through engineering enhanced resistance against serpin mediated inhibition. PLoS One 2019,14(5)","journal-title":"PLoS One"},{"key":"ref=266","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/sj.eye.6702931","volume":"22","author":"Chen W.","year":"2008","unstructured":"Chen W.; Huang X.; Ma X.W.; Mo W.; Wang W.J.; Song H.Y.; Enzymatic vitreolysis with recombinant microplasminogen and tissue plasminogen activator. Eye (Lond) 2008,22(2),300-307","journal-title":"Eye (Lond)"},{"key":"ref=267","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1167\/iovs.08-2185","volume":"50","author":"de Smet M.D.","year":"2009","unstructured":"de Smet M.D.; Valmaggia C.; Zarranz-Ventura J.; Willekens B.; Microplasmin: Ex vivo characterization of its activity in porcine vitreous. Invest Ophthalmol Vis Sci 2009,50(2),814-819","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=268","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ophtha.2014.07.045","volume":"122","author":"Haller J.A.","year":"2015","unstructured":"Haller J.A.; Stalmans P.; Benz M.S.; Gandorfer A.; Pakola S.J.; Girach A.; Kampik A.; Jaffe G.J.; Toth C.A.; Grp M-T.S.; Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: Subgroup analyses from two randomized trials. Ophthalmology 2015,122(1),117-122","journal-title":"Ophthalmology"},{"key":"ref=269","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1136\/bjophthalmol-2016-309190","volume":"100","author":"de Smet M.D.","year":"2016","unstructured":"de Smet M.D.; Stassen J.M.; Meenink T.C.M.; Janssens T.; Vanheukelom V.; Naus G.J.L.; Beelen M.J.; Jonckx B.; Release of experimental retinal vein occlusions by direct intraluminal injection of ocriplasmin. Br J Ophthalmol 2016,100(12),1742-1746","journal-title":"Br J Ophthalmol"},{"key":"ref=270","author":"Willekens K.","unstructured":"Willekens K.; Gijbels A.; Smits J.; Schoevaerdts L.; Blanckaert J.; Feyen J.H.M.; Reynaerts D.; Stalmans P.; Phase I trial on robot assisted retinal vein cannulation with ocriplasmin infusion for central retinal vein occlusion Acta Ophthalmologica,","journal-title":"Phase I trial on robot assisted retinal vein cannulation with ocriplasmin infusion for central retinal vein occlusion Acta Ophthalmologica,"},{"key":"ref=271","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1160\/TH08-04-0225","volume":"100","author":"Hunt J.A.","year":"2008","unstructured":"Hunt J.A.; Petteway S.R.; Scuderi P.; Novokhatny V.; Simplified recombinant plasmin: Production and functional comparison of a novel thrombolytic molecule with plasma-derived plasmin. Thromb Haemost 2008,100(3),413-419","journal-title":"Thromb Haemost"},{"key":"ref=272","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1007\/BF01956052","volume":"43","author":"Sumi H.","year":"1987","unstructured":"Sumi H.; Hamada H.; Tsushima H.; Mihara H.; Muraki H.; A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet. Experientia 1987,43(10),1110-1111","journal-title":"Experientia"},{"key":"ref=273","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000252817","volume":"36","author":"Yatagai C.","year":"2008","unstructured":"Yatagai C.; Maruyama M.; Kawahara T.; Sumi H.; Nattokinase-promoted tissue plasminogen activator release from human cells. Pathophysiol Haemost Thromb 2008,36(5),227-232","journal-title":"Pathophysiol Haemost Thromb"},{"key":"ref=274","doi-asserted-by":"publisher","first-page":"24690","DOI":"10.1074\/jbc.M101751200","volume":"276","author":"Urano T.","year":"2001","unstructured":"Urano T.; Ihara H.; Umemura K.; Suzuki Y.; Oike M.; Akita S.; Tsukamoto Y.; Suzuki I.; Takada A.; The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis Cleaves and inactivates plasminogen activator inhibitor type 1. J Biol Chem 2001,276(27),24690-24696","journal-title":"J Biol Chem"},{"key":"ref=275","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0268-9499(95)80005-0","volume":"9","author":"Fujita M.","year":"1995","unstructured":"Fujita M.; Ito Y.; Hong K.; Nishimuro S.; Characterization of nattokinase-degraded products from human fibrinogen or cross-linked fibrin. Fibrinolysis 1995,9(3),157-164","journal-title":"Fibrinolysis"},{"key":"ref=276","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000205051","volume":"84","author":"Sumi H.","year":"1990","unstructured":"Sumi H.; Hamada H.; Nakanishi K.; Hiratani H.; Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase. Acta Haematol 1990,84(3),139-143","journal-title":"Acta Haematol"},{"key":"ref=277","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1006\/bbrc.1993.2624","volume":"197","author":"Fujita M.","year":"1993","unstructured":"Fujita M.; Nomura K.; Hong K.; Ito Y.; Asada A.; Nishimuro S.; Purification and characterization of a strong fibrinolytic enzyme (nattokinase) in the vegetable cheese natto, a popular soybean fermented food in Japan. Biochem Biophys Res Commun 1993,197(3),1340-1347","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=278","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.nutres.2009.01.009","volume":"29","author":"Hsia C.H.","year":"2009","unstructured":"Hsia C.H.; Shen M.C.; Lin J.S.; Wen Y.K.; Hwang K.L.; Cham T.M.; Yang N.C.; Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects. Nutr Res 2009,29(3),190-196","journal-title":"Nutr Res"},{"key":"ref=279","doi-asserted-by":"publisher","first-page":"11601","DOI":"10.1038\/srep11601","volume":"5","author":"Kurosawa Y.","year":"2015","unstructured":"Kurosawa Y.; Nirengi S.; Homma T.; Esaki K.; Ohta M.; Clark J.F.; Hamaoka T.; A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Sci Rep 2015,5,11601","journal-title":"Sci Rep"},{"key":"ref=280","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/IBPC.S99553","volume":"9","author":"Jensen G.S.","year":"2016","unstructured":"Jensen G.S.; Lenninger M.; Ero M.P.; Benson K.F.; Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: Results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial. Integr Blood Press Control 2016,9,95-104","journal-title":"Integr Blood Press Control"},{"key":"ref=281","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1089\/jmf.2019.0183","volume":"23","author":"Pham P.T.","year":"2020","unstructured":"Pham P.T.; Han B.; Hoang B.X.; Nattospes as effective and safe functional supplements in management of stroke. J Med Food 2020,23(8),879-885","journal-title":"J Med Food"},{"key":"ref=282","doi-asserted-by":"publisher","DOI":"10.1177\/1177271918785130","volume":"13","author":"Chen H.","year":"2018","unstructured":"Chen H.; McGowan E.M.; Ren N.; Lal S.; Nassif N.; Shad-Kaneez F.; Qu X.; Lin Y.; Nattokinase: a promising alternative in prevention and treatment of cardiovascular diseases. Biomark Insights 2018,13","journal-title":"Biomark Insights"},{"key":"ref=283","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40265-019-01079-z","volume":"79","author":"Lichter-Konecki U.","year":"2019","unstructured":"Lichter-Konecki U.; Vockley J.; Phenylketonuria: Current Treatments and Future Developments. Drugs 2019,79(5),495-500","journal-title":"Drugs"},{"key":"ref=284","first-page":"304","volume":"4","author":"Al Hafid N.","year":"2015","unstructured":"Al Hafid N.; Christodoulou J.; Phenylketonuria: A review of current and future treatments. Transl Pediatr 2015,4(4),304-317","journal-title":"Transl Pediatr"},{"key":"ref=285","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/gim.2013.157","volume":"16","author":"Vockley J.","year":"2014","unstructured":"Vockley J.; Andersson H.C.; Antshel K.M.; Braverman N.E.; Burton B.K.; Frazier D.M.; Mitchell J.; Smith W.E.; Thompson B.H.; Berry S.A.; Phenylalanine hydroxylase deficiency: Diagnosis and management guideline. Genet Med 2014,16(2),188-200","journal-title":"Genet Med"},{"key":"ref=286","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/GIM.0b013e3182141b48","volume":"13","author":"Mitchell J.J.","year":"2011","unstructured":"Mitchell J.J.; Trakadis Y.J.; Scriver C.R.; Phenylalanine hydroxylase deficiency. Genet Med 2011,13(8),697-707","journal-title":"Genet Med"},{"key":"ref=287","doi-asserted-by":"publisher","DOI":"10.1177\/1177392819857089","volume":"13","author":"Hydery T.","year":"2019","unstructured":"Hydery T.; Coppenrath V.A.; A comprehensive review of pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria. Drug Target Insights 2019,13","journal-title":"Drug Target Insights"},{"key":"ref=288","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ymgme.2019.05.006","volume":"128","author":"Hausmann O.","year":"2019","unstructured":"Hausmann O.; Daha M.; Longo N.; Knol E.; M&#xFC;ller I.; Northrup H.; Brockow K.; Pegvaliase: Immunological profile and recommendations for the clinical management of hypersensitivity reactions in patients with phenylketonuria treated with this enzyme substitution therapy. Mol Genet Metab 2019,128(1-2),84-91","journal-title":"Mol Genet Metab"},{"key":"ref=289","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s11095-017-2167-6","volume":"34","author":"Ronda L.","year":"2017","unstructured":"Ronda L.; Marchetti M.; Piano R.; Liuzzi A.; Corsini R.; Percudani R.; Bettati S.; A Trivalent Enzymatic System for Uricolytic Therapy of HPRT Deficiency and Lesch-Nyhan Disease. Pharm Res 2017,34(7),1477-1490","journal-title":"Pharm Res"},{"key":"ref=290","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jconrel.2014.02.002","volume":"180","author":"Pfister D.","year":"2014","unstructured":"Pfister D.; Morbidelli M.; Process for protein PEGylation. J Control Release 2014,180,134-149","journal-title":"J Control Release"},{"key":"ref=291","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jconrel.2011.10.037","volume":"161","author":"Pasut G.","year":"2012","unstructured":"Pasut G.; Veronese F.M.; State of the art in PEGylation: The great versatility achieved after forty years of research. J Control Release 2012,161(2),461-472","journal-title":"J Control Release"},{"key":"ref=292","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1039\/c2cs15289d","volume":"41","author":"Kontos S.","year":"2012","unstructured":"Kontos S.; Hubbell J.A.; Drug development: Longer-lived proteins. Chem Soc Rev 2012,41(7),2686-2695","journal-title":"Chem Soc Rev"},{"key":"ref=293","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/4671051a","volume":"467","author":"Hubbell J.A.","year":"2010","unstructured":"Hubbell J.A.; Drug development: Longer-lived proteins. Nature 2010,467(7319),1051-1052","journal-title":"Nature"},{"key":"ref=294","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1073\/pnas.96.5.2339","volume":"96","author":"Sarkissian C.N.","year":"1999","unstructured":"Sarkissian C.N.; Shao Z.; Blain F.; Peevers R.; Su H.; Heft R.; Chang T.M.; Scriver C.R.; A different approach to treatment of phenylketonuria: Phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc Natl Acad Sci USA 1999,96(5),2339-2344","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=295","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1021\/bi061774g","volume":"46","author":"Moffitt M.C.","year":"2007","unstructured":"Moffitt M.C.; Louie G.V.; Bowman M.E.; Pence J.; Noel J.P.; Moore B.S.; Discovery of two cyanobacterial phenylalanine ammonia lyases: Kinetic and structural characterization. Biochemistry 2007,46(4),1004-1012","journal-title":"Biochemistry"},{"key":"ref=296","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.1039\/D0CC00783H","volume":"56","author":"Mays Z.J.","year":"2020","unstructured":"Mays Z.J.; Mohan K.; Trivedi V.D.; Chappell T.C.; Nair N.U.; Directed evolution of Anabaena variabilis phenylalanine ammonia-lyase (PAL) identifies mutants with enhanced activities. Chem Commun (Camb) 2020,56(39),5255-5258","journal-title":"Chem Commun (Camb)"},{"key":"ref=297","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nbt.4222","volume":"36","author":"Isabella V.M.","year":"2018","unstructured":"Isabella V.M.; Ha B.N.; Castillo M.J.; Lubkowicz D.J.; Rowe S.E.; Millet Y.A.; Anderson C.L.; Li N.; Fisher A.B.; West K.A.; Reeder P.J.; Momin M.M.; Bergeron C.G.; Guilmain S.E.; Miller P.F.; Kurtz C.B.; Falb D.; Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat Biotechnol 2018,36(9),857-864","journal-title":"Nat Biotechnol"},{"key":"ref=298","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1096\/fasebj.6.10.1378801","volume":"6","author":"McIntosh I.","year":"1992","unstructured":"McIntosh I.; Cutting G.R.; Cystic fibrosis transmembrane conductance regulator and the etiology and pathogenesis of cystic fibrosis. FASEB J 1992,6(10),2775-2782","journal-title":"FASEB J"},{"key":"ref=299","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1056\/NEJMra043184","volume":"352","author":"Rowe S.M.","year":"2005","unstructured":"Rowe S.M.; Miller S.; Sorscher E.J.; Cystic fibrosis. N Engl J Med 2005,352(19),1992-2001","journal-title":"N Engl J Med"},{"key":"ref=300","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","volume":"373","author":"O\u2019Sullivan B.P.","year":"2009","unstructured":"O\u2019Sullivan B.P.; Freedman S.D.; Cystic fibrosis. Lancet 2009,373(9678),1891-1904","journal-title":"Lancet"},{"key":"ref=301","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"Elborn J.S.","year":"2016","unstructured":"Elborn J.S.; Cystic fibrosis. Lancet 2016,388(10059),2519-2531","journal-title":"Lancet"},{"key":"ref=302","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1164\/rccm.201504-0656UP","volume":"192","author":"Ong T.","year":"2015","unstructured":"Ong T.; Ramsey B.W.; Update in Cystic Fibrosis 2014. Am J Respir Crit Care Med 2015,192(6),669-675","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=303","doi-asserted-by":"publisher","first-page":"482","DOI":"10.7861\/clinmedicine.13-5-482","volume":"13","author":"Nazareth D.","year":"2013","unstructured":"Nazareth D.; Walshaw M.; Coming of age in cystic fibrosis-transition from paediatric to adult care. Clin Med (Lond) 2013,13(5),482-486","journal-title":"Clin Med (Lond)"},{"key":"ref=304","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1152\/physrev.1999.79.1.S23","volume":"79","author":"Sheppard D.N.","year":"1999","unstructured":"Sheppard D.N.; Welsh M.J.; Structure and function of the CFTR chloride channel. Physiol Rev 1999,79(1)(Suppl.),S23-S45","journal-title":"Physiol Rev"},{"key":"ref=305","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/humu.10041","volume":"19","author":"Bobadilla J.L.","year":"2002","unstructured":"Bobadilla J.L.; Macek M.; Fine J.P.; Farrell P.M.; Cystic fibrosis: A worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. Hum Mutat 2002,19(6),575-606","journal-title":"Hum Mutat"},{"key":"ref=306","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112436","volume":"200","author":"Sharma J.","year":"2020","unstructured":"Sharma J.; Keeling K.M.; Rowe S.M.; Pharmacological approaches for targeting cystic fibrosis nonsense mutations. Eur J Med Chem 2020,200","journal-title":"Eur J Med Chem"},{"key":"ref=307","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1002\/ppul.23773","volume":"52","author":"Guimbellot J.","year":"2017","unstructured":"Guimbellot J.; Sharma J.; Rowe S.M.; Toward inclusive therapy with CFTR modulators: Progress and challenges. Pediatr Pulmonol 2017,52(S48),S4-S14","journal-title":"Pediatr Pulmonol"},{"key":"ref=308","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S2213-2600(17)30311-9","volume":"5","author":"Elborn J.S.","year":"2017","unstructured":"Elborn J.S.; Davies J.; Clinical trial research in focus: Ensuring new cystic fibrosis drugs fulfil their potential. Lancet Respir Med 2017,5(9),681-683","journal-title":"Lancet Respir Med"},{"key":"ref=309","doi-asserted-by":"publisher","first-page":"L928","DOI":"10.1152\/ajplung.00395.2015","volume":"310","author":"Birket S.E.","year":"2016","unstructured":"Birket S.E.; Chu K.K.; Houser G.H.; Liu L.; Fernandez C.M.; Solomon G.M.; Lin V.; Shastry S.; Mazur M.; Sloane P.A.; Hanes J.; Grizzle W.E.; Sorscher E.J.; Tearney G.J.; Rowe S.M.; Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy. Am J Physiol Lung Cell Mol Physiol 2016,310(10),L928-L939","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref=310","volume":"9","author":"Yang C.","year":"2018","unstructured":"Yang C.; Montgomery M.; Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev 2018,9","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=311","first-page":"65","volume":"21","author":"Yang C.L.","year":"2017","unstructured":"Yang C.L.; Chilvers M.; Montgomery M.; Nolan S.J.; Dornase alfa for cystic fibrosis. Paediatr Respir Rev 2017,21,65-67","journal-title":"Paediatr Respir Rev"},{"key":"ref=312","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/jama.1968.03140310070022","volume":"205","author":"Lieberman J.","year":"1968","unstructured":"Lieberman J.; Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. JAMA 1968,205(5),312-313","journal-title":"JAMA"},{"key":"ref=313","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1177\/106002809603000614","volume":"30","author":"Cramer G.W.","year":"1996","unstructured":"Cramer G.W.; Bosso J.A.; The role of dornase alfa in the treatment of cystic fibrosis. Ann Pharmacother 1996,30(6),656-661","journal-title":"Ann Pharmacother"},{"key":"ref=314","doi-asserted-by":"publisher","first-page":"10250","DOI":"10.1021\/bi300873f","volume":"51","author":"Parsiegla G.","year":"2012","unstructured":"Parsiegla G.; Noguere C.; Santell L.; Lazarus R.A.; Bourne Y.; The structure of human DNase I bound to magnesium and phosphate ions points to a catalytic mechanism common to members of the DNase I-like superfamily. Biochemistry 2012,51(51),10250-10258","journal-title":"Biochemistry"},{"key":"ref=315","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(95)91460-9","volume":"346","author":"Collier J.","year":"1995","unstructured":"Collier J.; Dornase-alfa and orphan drugs. Lancet 1995,346(8975),633-633","journal-title":"Lancet"},{"key":"ref=316","doi-asserted-by":"publisher","first-page":"9188","DOI":"10.1073\/pnas.87.23.9188","volume":"87","author":"Shak S.","year":"1990","unstructured":"Shak S.; Capon D.J.; Hellmiss R.; Marsters S.A.; Baker C.L.; Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990,87(23),9188-9192","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=317","first-page":"234","volume":"48","author":"Erdeve O.","year":"2007","unstructured":"Erdeve O.; Uras N.; Atasay B.; Arsan S.; Efficacy and safety of nebulized recombinant human DNase as rescue treatment for persistent atelectasis in newborns: Case-series. Croat Med J 2007,48(2),234-239","journal-title":"Croat Med J"},{"key":"ref=318","doi-asserted-by":"publisher","first-page":"R351","DOI":"10.1186\/cc3544","volume":"9","author":"Hendriks T.","year":"2005","unstructured":"Hendriks T.; de Hoog M.; Lequin M.H.; Devos A.S.; Merkus P.J.F.M.; DNase and atelectasis in non-cystic fibrosis pediatric patients. Crit Care 2005,9(4),R351-R356","journal-title":"Crit Care"},{"key":"ref=319","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1126\/science.1092385","volume":"303","author":"Brinkmann V.","year":"2004","unstructured":"Brinkmann V.; Reichard U.; Goosmann C.; Fauler B.; Uhlemann Y.; Weiss D.S.; Weinrauch Y.; Zychlinsky A.; Neutrophil extracellular traps kill bacteria. Science 2004,303(5663),1532-1535","journal-title":"Science"},{"key":"ref=320","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028526","volume":"6","author":"Papayannopoulos V.","year":"2011","unstructured":"Papayannopoulos V.; Staab D.; Zychlinsky A.; Neutrophil elastase enhances sputum solubilization in cystic fibrosis patients receiving DNase therapy. PLoS One 2011,6(12)","journal-title":"PLoS One"},{"key":"ref=321","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200652","volume":"217","author":"Barnes B.J.","year":"2020","unstructured":"Barnes B.J.; Adrover J.M.; Baxter-Stoltzfus A.; Borczuk A.; Cools-Lartigue J.; Crawford J.M.; Da&#xDF;ler-Plenker J.; Guerci P.; Huynh C.; Knight J.S.; Loda M.; Looney M.R.; McAllister F.; Rayes R.; Renaud S.; Rousseau S.; Salvatore S.; Schwartz R.E.; Spicer J.D.; Yost C.C.; Weber A.; Zuo Y.; Egeblad M.; Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med 2020,217(6)","journal-title":"J Exp Med"},{"key":"ref=322","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1432-1033.1981.tb05193.x","volume":"114","author":"Skovbjerg H.","year":"1981","unstructured":"Skovbjerg H.; Sj&#xF6;str&#xF6;m H.; Nor&#xE9;n O.; Purification and characterisation of amphiphilic lactase\/phlorizin hydrolase from human small intestine. Eur J Biochem 1981,114(3),653-661","journal-title":"Eur J Biochem"},{"key":"ref=323","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev.genet.37.110801.143820","volume":"37","author":"Swallow D.M.","year":"2003","unstructured":"Swallow D.M.; Genetics of lactase persistence and lactose intolerance. Annu Rev Genet 2003,37,197-219","journal-title":"Annu Rev Genet"},{"key":"ref=324","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1002\/j.1460-2075.1988.tb03124.x","volume":"7","author":"Mantei N.","year":"1988","unstructured":"Mantei N.; Villa M.; Enzler T.; Wacker H.; Boll W.; James P.; Hunziker W.; Semenza G.; Complete primary structure of human and rabbit lactase-phlorizin hydrolase: Implications for biosynthesis, membrane anchoring and evolution of the enzyme. EMBO J 1988,7(9),2705-2713","journal-title":"EMBO J"},{"key":"ref=325","doi-asserted-by":"publisher","DOI":"10.3390\/nu10111599","volume":"10","author":"Fassio F.","year":"2018","unstructured":"Fassio F.; Facioni M.S.; Guagnini F.; Lactose Maldigestion, Malabsorption, and Intolerance: A Comprehensive Review with a Focus on Current Management and Future Perspectives. Nutrients 2018,10(11)","journal-title":"Nutrients"},{"key":"ref=326","doi-asserted-by":"publisher","DOI":"10.3390\/nu12051487","volume":"12","author":"Leis R.","year":"2020","unstructured":"Leis R.; de Castro M.J.; de Lamas C.; Pic&#xE1;ns R.; Couce M.L.; Effects of prebiotic and probiotic supplementation on lactase deficiency and lactose intolerance: a systematic review of controlled trials. Nutrients 2020,12(5)","journal-title":"Nutrients"},{"key":"ref=327","doi-asserted-by":"publisher","DOI":"10.3390\/nu10121994","volume":"10","author":"Szilagyi A.","year":"2018","unstructured":"Szilagyi A.; Ishayek N.; Lactose intolerance, dairy avoidance, and treatment options. Nutrients 2018,10(12)","journal-title":"Nutrients"},{"key":"ref=328","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/j.1365-2362.2008.02035.x","volume":"38","author":"Portincasa P.","year":"2008","unstructured":"Portincasa P.; Di Ciaula A.; Vacca M.; Montelli R.; Wang D.Q.; Palasciano G.; Beneficial effects of oral tilactase on patients with hypolactasia. Eur J Clin Invest 2008,38(11),835-844","journal-title":"Eur J Clin Invest"},{"key":"ref=329","first-page":"163","volume":"14","author":"Ojetti V.","year":"2010","unstructured":"Ojetti V.; Gigante G.; Gabrielli M.; Ainora M.E.; Mannocci A.; Lauritano E.C.; Gasbarrini G.; Gasbarrini A.; The effect of oral supplementation with Lactobacillus reuteri or tilactase in lactose intolerant patients: Randomized trial. Eur Rev Med Pharmacol Sci 2010,14(3),163-170","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=330","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.clnu.2014.06.012","volume":"34","author":"de Vrese M.","year":"2015","unstructured":"de Vrese M.; Laue C.; Offick B.; Soeth E.; Repenning F.; Tho&#xDF; A.; Schrezenmeir J.; A combination of acid lactase from Aspergillus oryzae and yogurt bacteria improves lactose digestion in lactose maldigesters synergistically: A randomized, controlled, double-blind cross-over trial. Clin Nutr 2015,34(3),394-399","journal-title":"Clin Nutr"},{"key":"ref=331","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/680196","volume":"2014","author":"Ibba I.","year":"2014","unstructured":"Ibba I.; Gilli A.; Boi M.F.; Usai P.; Effects of exogenous lactase administration on hydrogen breath excretion and intestinal symptoms in patients presenting lactose malabsorption and intolerance. BioMed Res Int 2014,2014","journal-title":"BioMed Res Int"},{"key":"ref=332","volume":"7","year":"2009","unstructured":"Scientific Opinion on the substantiation of health claims related to zinc and function of the immune system (ID 291, 1757), DNA synthesis and cell division (ID 292, 1759), protection of DNA, proteins and lipids from oxidative damage (ID 294, 1758), maintenance of bone (ID 295, 1756), cognitive function (ID 296), fertility and reproduction (ID 297, 300), reproductive development (ID 298), muscle function (ID 299), metabolism of fatty acids (ID 302), maintenance of joints (ID 305), function of the heart and blood vessels (ID 306), prostate function (ID 307), thyroid function (ID 308), acid-base metabolism (ID 360), vitamin A metabolism (ID 361) and maintenance of vision (ID 361) pursuant to Article 13(1) of Regulation (EC) No 1924\/2006. EFSA. EFSA J 2009,7(9)","journal-title":"EFSA J"},{"key":"ref=333","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/ard.45.6.441","volume":"45","author":"Jenner J.R.","year":"1986","unstructured":"Jenner J.R.; Buttle D.J.; Dixon A.K.; Mechanism of action of intradiscal chymopapain in the treatment of sciatica: A clinical, biochemical, and radiological study. Ann Rheum Dis 1986,45(6),441-449","journal-title":"Ann Rheum Dis"},{"key":"ref=334","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1358\/dot.2019.55.1.2899445","volume":"55","author":"Matsuyama Y.","year":"2019","unstructured":"Matsuyama Y.; Chiba K.; Condoliase for treatment of lumbar disc herniation. Drugs Today (Barc) 2019,55(1),17-23","journal-title":"Drugs Today (Barc)"},{"key":"ref=335","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S0021-9258(18)60289-3","volume":"237","author":"Ebata M.","year":"1962","unstructured":"Ebata M.; Yasunobu K.T.; Chymopapain I.; Chymopapain I.; Isolation, crystallization, and preliminary characterization. J Biol Chem 1962,237,1086-1094","journal-title":"J Biol Chem"},{"key":"ref=336","doi-asserted-by":"publisher","first-page":"16292","DOI":"10.1021\/bi961491w","volume":"35","author":"Maes D.","year":"1996","unstructured":"Maes D.; Bouckaert J.; Poortmans F.; Wyns L.; Looze Y.; Structure of chymopapain at 1.7 A resolution. Biochemistry 1996,35(50),16292-16298","journal-title":"Biochemistry"},{"key":"ref=337","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00586-010-1411-0","volume":"19","author":"Henschke N.","year":"2010","unstructured":"Henschke N.; Kuijpers T.; Rubinstein S.M.; van Middelkoop M.; Ostelo R.; Verhagen A.; Koes B.W.; van Tulder M.W.; Injection therapy and denervation procedures for chronic low-back pain: A systematic review. Eur Spine J 2010,19(9),1425-1449","journal-title":"Eur Spine J"},{"key":"ref=338","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3109\/01480548409035110","volume":"7","author":"Simmons J.W.","year":"1984","unstructured":"Simmons J.W.; Upman P.J.; Stavinoha W.B.; Pharmacologic and toxicologic profile of chymopapain B (Chemolase). Drug Chem Toxicol 1984,7(3),299-314","journal-title":"Drug Chem Toxicol"},{"key":"ref=339","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3171\/jns.1987.66.5.0775","volume":"66","author":"Cusick J.F.","year":"1987","unstructured":"Cusick J.F.; Ho K.C.; Schamberg J.F.; Subarachnoid hemorrhage following chymopapain chemonucleolysis. Case report. J Neurosurg 1987,66(5),775-778","journal-title":"J Neurosurg"},{"key":"ref=340","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/00007632-198505000-00012","volume":"10","author":"Dyck P.","year":"1985","unstructured":"Dyck P.; Paraplegia following chemonucleolysis. A case report and discussion of neurotoxicity. Spine 1985,10(4),359-362","journal-title":"Spine"},{"key":"ref=341","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1227\/00006123-198502000-00017","volume":"16","author":"Buchman A.","year":"1985","unstructured":"Buchman A.; Wright R.B.; Wichter M.D.; Whisler W.W.; Bosch A.; Hemorrhagic complications after the lumbar injection of chymopapain. Neurosurgery 1985,16(2),222-224","journal-title":"Neurosurgery"},{"key":"ref=342","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.21037\/jss.2019.04.24","volume":"5","author":"Ishibashi K.","year":"2019","unstructured":"Ishibashi K.; Iwai H.; Koga H.; Chemonucleolysis with chondroitin sulfate ABC endolyase as a novel minimally invasive treatment for patients with lumbar intervertebral disc herniation. J Spine Surg 2019,5(Suppl. 1),S115-S121","journal-title":"J Spine Surg"},{"key":"ref=343","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/00007632-198705000-00016","volume":"12","author":"Hedtmann A.","year":"1987","unstructured":"Hedtmann A.; Steffen R.; Kr&#xE4;mer J.; Prospective comparative study of intradiscal high-dose and low-dose collagenase Versus chymopapain. Spine 1987,12(4),388-392","journal-title":"Spine"},{"key":"ref=344","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3171\/jns.1986.64.3.0474","volume":"64","author":"Zook B.C.","year":"1986","unstructured":"Zook B.C.; Kobrine A.I.; Effects of collagenase and chymopapain on spinal nerves and intervertebral discs of cynomolgus monkeys. J Neurosurg 1986,64(3),474-483","journal-title":"J Neurosurg"},{"key":"ref=345","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1001\/jama.1981.03310320052026","volume":"245","author":"Sussman B.J.","year":"1981","unstructured":"Sussman B.J.; Bromley J.W.; Gomez J.C.; Injection of collagenase in the treatment of herniated lumbar disk. Initial clinical report. JAMA 1981,245(7),730-732","journal-title":"JAMA"},{"key":"ref=346","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0022-2836(03)00345-0","volume":"328","author":"Huang W.","year":"2003","unstructured":"Huang W.; Lunin V.V.; Li Y.; Suzuki S.; Sugiura N.; Miyazono H.; Cygler M.; Crystal structure of Proteus vulgaris chondroitin sulfate ABC lyase I at 1.9A resolution. J Mol Biol 2003,328(3),623-634","journal-title":"J Mol Biol"},{"key":"ref=347","doi-asserted-by":"publisher","DOI":"10.3390\/catal9040322","volume":"9","author":"Benito-Arenas R.","year":"2019","unstructured":"Benito-Arenas R.; Zarate S.G.; Revuelta J.; Bastida A.; Chondroitin sulfate-degrading enzymes as tools for the development of new pharmaceuticals. Catalysts 2019,9(4)","journal-title":"Catalysts"},{"key":"ref=348","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc6378","volume":"6","author":"Hettiaratchi M.H.","year":"2020","unstructured":"Hettiaratchi M.H.; O\u2019Meara M.J.; O\u2019Meara T.R.; Pickering A.J.; Letko-Khait N.; Shoichet M.S.; Reengineering biocatalysts: Computational redesign of chondroitinase ABC improves efficacy and stability. Sci Adv 2020,6(34)","journal-title":"Sci Adv"},{"key":"ref=349","doi-asserted-by":"publisher","first-page":"E869","DOI":"10.1097\/BRS.0000000000002528","volume":"43","author":"Chiba K.","year":"2018","unstructured":"Chiba K.; Matsuyama Y.; Seo T.; Toyama Y.; Condoliase for the treatment of lumbar disc herniation: a randomized controlled trial. Spine 2018,43(15),E869-E876","journal-title":"Spine"},{"key":"ref=350","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3171\/2017.7.SPINE161327","volume":"28","author":"Matsuyama Y.","year":"2018","unstructured":"Matsuyama Y.; Chiba K.; Iwata H.; Seo T.; Toyama Y.; A multicenter, randomized, double-blind, dose-finding study of condoliase in patients with lumbar disc herniation. J Neurosurg Spine 2018,28(5),499-511","journal-title":"J Neurosurg Spine"},{"key":"ref=351","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1749-6632.1999.tb07671.x","volume":"878","author":"Pilcher B.K.","year":"1999","unstructured":"Pilcher B.K.; Wang M.; Qin X.J.; Parks W.C.; Senior R.M.; Welgus H.G.; Role of matrix metalloproteinases and their inhibition in cutaneous wound healing and allergic contact hypersensitivity. Ann N Y Acad Sci 1999,878,12-24","journal-title":"Ann N Y Acad Sci"},{"key":"ref=352","first-page":"506","volume":"11","author":"Vogel W.F.","year":"2001","unstructured":"Vogel W.F.; Collagen-receptor signaling in health and disease. Eur J Dermatol 2001,11(6),506-514","journal-title":"Eur J Dermatol"},{"key":"ref=353","doi-asserted-by":"publisher","first-page":"23959","DOI":"10.1074\/jbc.273.37.23959","volume":"273","author":"Balb&#xED;n M.","year":"1998","unstructured":"Balb&#xED;n M.; Fueyo A.; Kn&#xE4;uper V.; Pend&#xE1;s A.M.; L&#xF3;pez J.M.; Jim&#xE9;nez M.G.; Murphy G.; L&#xF3;pez-Ot&#xED;n C.; Collagenase 2 (MMP-8) expression in murine tissue-remodeling processes. Analysis of its potential role in postpartum involution of the uterus. J Biol Chem 1998,273(37),23959-23968","journal-title":"J Biol Chem"},{"key":"ref=354","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3109\/1040841X.2014.904270","volume":"42","author":"Duarte A.S.","year":"2016","unstructured":"Duarte A.S.; Correia A.; Esteves A.C.; Bacterial collagenases-A review. Crit Rev Microbiol 2016,42(1),106-126","journal-title":"Crit Rev Microbiol"},{"key":"ref=355","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1073\/pnas.54.4.1197","volume":"54","author":"Gross J.","year":"1965","unstructured":"Gross J.; Nagai Y.; Specific degradation of the collagen molecule by tadpole collagenolytic enzyme. Proc Natl Acad Sci USA 1965,54(4),1197-1204","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=356","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jprot.2013.10.004","volume":"100","author":"Eckhard U.","year":"2014","unstructured":"Eckhard U.; Huesgen P.F.; Brandstetter H.; Overall C.M.; Proteomic protease specificity profiling of clostridial collagenases reveals their intrinsic nature as dedicated degraders of collagen. J Proteomics 2014,100(100),102-114","journal-title":"J Proteomics"},{"key":"ref=357","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1021\/bi00308a035","volume":"23","author":"Bond M.D.","year":"1984","unstructured":"Bond M.D.; Van Wart H.E.; Purification and separation of individual collagenases of Clostridium histolyticum using red dye ligand chromatography. Biochemistry 1984,23(13),3077-3085","journal-title":"Biochemistry"},{"key":"ref=358","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1021\/bi00308a036","volume":"23","author":"Bond M.D.","year":"1984","unstructured":"Bond M.D.; Van Wart H.E.; Characterization of the individual collagenases from Clostridium histolyticum. Biochemistry 1984,23(13),3085-3091","journal-title":"Biochemistry"},{"key":"ref=359","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1021\/bi00308a037","volume":"23","author":"Bond M.D.","year":"1984","unstructured":"Bond M.D.; Van Wart H.E.; Relationship between the individual collagenases of Clostridium histolyticum: Evidence for evolution by gene duplication. Biochemistry 1984,23(13),3092-3099","journal-title":"Biochemistry"},{"key":"ref=360","author":"Worthington K.","year":"2011","unstructured":"Worthington K.; Worthington V.; Worthington Enzyme Manual Available from:2011 http:\/\/www.worthington-biochem.com\/pap\/default.html Worthington Biochemical Corporation.","journal-title":"Worthington Enzyme Manual"},{"key":"ref=361","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/BF01025095","volume":"11","author":"French M.F.","year":"1992","unstructured":"French M.F.; Bhown A.; Van Wart H.E.; Identification of Clostridium histolyticum collagenase hyperreactive sites in type I, II, and III collagens: Lack of correlation with local triple helical stability. J Protein Chem 1992,11(1),83-97","journal-title":"J Protein Chem"},{"key":"ref=362","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1128\/JB.181.3.923-933.1999","volume":"181","author":"Matsushita O.","year":"1999","unstructured":"Matsushita O.; Jung C.M.; Katayama S.; Minami J.; Takahashi Y.; Okabe A.; Gene duplication and multiplicity of collagenases in Clostridium histolyticum. J Bacteriol 1999,181(3),923-933","journal-title":"J Bacteriol"},{"key":"ref=363","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/nsmb.2127","volume":"18","author":"Eckhard U.","year":"2011","unstructured":"Eckhard U.; Sch&#xF6;nauer E.; N&#xFC;ss D.; Brandstetter H.; Structure of collagenase G reveals a chew-and-digest mechanism of bacterial collagenolysis. Nat Struct Mol Biol 2011,18(10),1109-1114","journal-title":"Nat Struct Mol Biol"},{"key":"ref=364","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1093\/emboj\/cdg172","volume":"22","author":"Wilson J.J.","year":"2003","unstructured":"Wilson J.J.; Matsushita O.; Okabe A.; Sakon J.; A bacterial collagen-binding domain with novel calcium-binding motif controls domain orientation. EMBO J 2003,22(8),1743-1752","journal-title":"EMBO J"},{"key":"ref=365","doi-asserted-by":"publisher","first-page":"20184","DOI":"10.1074\/jbc.M112.448548","volume":"288","author":"Eckhard U.","year":"2013","unstructured":"Eckhard U.; Sch&#xF6;nauer E.; Brandstetter H.; Structural basis for activity regulation and substrate preference of clostridial collagenases G, H, and T. J Biol Chem 2013,288(28),20184-20194","journal-title":"J Biol Chem"},{"key":"ref=366","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s40265-015-0441-7","volume":"75","author":"Dhillon S.","year":"2015","unstructured":"Dhillon S.; Collagenase clostridium histolyticum: a review in Peyronie\u2019s disease. Drugs 2015,75(12),1405-1412","journal-title":"Drugs"},{"key":"ref=367","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1358\/dot.2011.47.9.1656502","volume":"47","author":"Kaplan F.T.","year":"2011","unstructured":"Kaplan F.T.; Collagenase clostridium histolyticum injection for the treatment of Dupuytren\u2019s contracture. Drugs Today (Barc) 2011,47(9),653-667","journal-title":"Drugs Today (Barc)"},{"key":"ref=368","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1097\/WON.0b013e3181bfdf83","volume":"36","author":"Ramundo J.","year":"2009","unstructured":"Ramundo J.; Gray M.; Collagenase for enzymatic debridement: A systematic review. J Wound Ostomy Continence Nurs 2009,36(6)(Suppl.),S4-S11","journal-title":"J Wound Ostomy Continence Nurs"},{"key":"ref=369","unstructured":"Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_ docs\/l abel\/2020\/761146s000lbl.pdf"},{"key":"ref=370","doi-asserted-by":"publisher","DOI":"10.1177\/1756287218823671","volume":"11","author":"Randhawa K.","year":"2019","unstructured":"Randhawa K.; Shukla C.J.; Non-invasive treatment in the management of Peyronie\u2019s disease. Ther Adv Urol 2019,11(11)","journal-title":"Ther Adv Urol"},{"key":"ref=371","unstructured":"Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_ docs\/label\/2018\/125338s109lbl.pdf"},{"key":"ref=372","unstructured":"Available from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xiapex-epar-product-information_it.pdf"},{"key":"ref=373","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1302\/2058-5241.4.180021","volume":"4","author":"Grazina R.","year":"2019","unstructured":"Grazina R.; Teixeira S.; Ramos R.; Sousa H.; Ferreira A.; Lemos R.; Dupuytren\u2019s disease: Where do we stand? EFORT Open Rev 2019,4(2),63-69","journal-title":"EFORT Open Rev"},{"key":"ref=374","doi-asserted-by":"publisher","first-page":"332","DOI":"10.4055\/cios.2019.11.3.332","volume":"11","author":"Nayar S.K.","year":"2019","unstructured":"Nayar S.K.; Pfisterer D.; Ingari J.V.; Collagenase Clostridium Histolyticum Injection for Dupuytren Contracture: 2-Year Follow-up. Clin Orthop Surg 2019,11(3),332-336","journal-title":"Clin Orthop Surg"},{"key":"ref=375","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1056\/NEJMoa0810866","volume":"361","author":"Hurst L.C.","year":"2009","unstructured":"Hurst L.C.; Badalamente M.A.; Hentz V.R.; Hotchkiss R.N.; Kaplan F.T.; Meals R.A.; Smith T.M.; Rodzvilla J.; Injectable collagenase clostridium histolyticum for Dupuytren\u2019s contracture. N Engl J Med 2009,361(10),968-979","journal-title":"N Engl J Med"},{"key":"ref=376","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"Gelbard M.","year":"2013","unstructured":"Gelbard M.; Goldstein I.; Hellstrom W.J.; McMahon C.G.; Smith T.; Tursi J.; Jones N.; Kaufman G.J.; Carson C.C.; III Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2013,190(1),199-207","journal-title":"J Urol"},{"key":"ref=377","doi-asserted-by":"publisher","DOI":"10.12968\/jowc.2019.28.Sup2.S9","author":"Pham C.H.","unstructured":"Pham C.H.; Collier Z.J.; Fang M.; Howell A.; Gillenwater T.J.; TJ The role of collagenase ointment in acute burns: A systematic review and meta-analysis J Wound Care, 2019, 28(Sup2), S9-S15","journal-title":"TJ The role of collagenase ointment in acute burns: A systematic review and meta-analysis J Wound Care, 2019, 28(Sup2), S9-S15"},{"key":"ref=378","unstructured":"Available from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nexobrid-epar-product-information_en. pdf"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867328666210713094722","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/194727\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867328666210713094722","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T04:41:07Z","timestamp":1672807267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/194727\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":378,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867328666210713094722","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}